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RESUMO 
O cancro é responsável por mais de 8 milhões de mortes por ano a nível mundial. Apesar de 
ser uma das terapêuticas mais utilizadas, a quimioterapia não é totalmente eficaz devido aos 
mecanismos de resistência, intrínseca ou adquirida, aos fármacos por parte das células 
tumorais, e devido à grande toxicidade nas células saudáveis. O desenvolvimento de 
nanomateriais, e.g. nanopartículas de ouro (AuNPs), surge na procura de um tratamento mais 
eficaz para o cancro. As AuNPs são produzidas para libertar e aumentar a concentração dos 
fármacos dentro das células tumorais. O grande objectivo deste trabalho foi o desenvolvimento 
de sistemas baseados em AuNPs – AuNPs@PEG@BSA e AuNPs@PEG@HSA - para veicular 
dois compostos metálicos com potencial anti-proliferativo, [Zn(Fendiona)2]Cl2 e 
[CoCl(H2O)(Fendiona)2]BF4, em linhas celulares de cancro colo-rectal (HCT116) e de cancro do 
pulmão (A549 e H1975). O desenvolvimento destes sistemas de AuNPs foi baseado na 
capacidade de interacção, anteriormente descrita, entre o composto TS265 e a HSA. As 
partículas e os nanoconjugados foram caracterizados por UV-Vis, TEM, DLS, ICP-MS, métodos 
de Bradford e de Ellman, permitindo confirmar a ligação das moléculas de PEG, BSA, HSA ou 
dos compostos à superfície. Os diâmetros hidrodinâmicos foram determinados por DLS em 
83,01 ± 1,43 nm, 88,60 ± 5,80 nm, 76,21 ± 1,55 nm e 84,67 ± 1,68 nm para as 
AuNPs@PEG@BSA-TS262, AuNPs@PEG@BSA-TS265, AuNPs@PEG@HSA-TS262 e 
AuNPs@PEG@HSA-TS265, respectivamente. As AuNPs que continham o composto TS265 
mostraram-se promissoras para o tratamento dos três tipos cancro testados, tendo a 
capacidade de reduzir a dose necessária de composto para atingir uma diminuição da 
viabilidade celular em 50 %. Em relação às AuNPs funcionalizadas com o composto TS262, 
apenas as AuNPs@PEG@HSA-TS262 se mostraram promissoras em HCT116.  
Termos-chave: bioconjugação, células tumorais, citotoxicidade, libertação de drogas, 
nanopartículas de ouro, nanotransportadores de drogas 
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ABSTRACT 
Cancer is responsible for more than 8 million deaths worldwide per year. Although being widely 
used, chemotherapy is not completely effective due to drug resistance mechanisms, intrinsic or 
acquired by cancer cells, and due to the higher toxicity in healthy cells. The development of 
nanomaterials, e.g. gold nanoparticles (AuNPs), arises in demand of more effective cancer 
treatments. AuNPs are produced to delivery and enhance the drug concentration inside cancer 
cells. The main goal of this work was the development of AuNPs-based systems – 
AuNPs@PEG@BSA and AuNPs@PEG@HSA - for the vectorisation of two metallic compounds 
with anti-proliferative potential, [Zn(Phendione)2]Cl2 and [CoCl(H2O)(Phendione)2]BF4 in 
colorectal cancer cell line (HCT116) and in lung cancer cell lines (A549 and H1975). The 
development of these AuNPs systems was based on the ability of the TS265 compound to 
interact with the HSA, previously described. The AuNPs and the nanoconjugates were 
characterised by UV-Vis, TEM, DLS, ICP-MS, Bradford and Ellman’s assays, allowing the 
confirmation of the binding of the PEG, BSA and HSA molecules or the compounds on the 
surface. The hydrodynamic diameters were determined by DLS in 83.01 ± 1.43 nm, 88.60 
± 5.80 nm, 76.21 ± 1.55 nm and 84.67 ± 1.68 nm for AuNPs@PEG@BSA-TS262, 
AuNPs@PEG@BSA-TS265, AuNPs@PEG@HSA-TS262 and AuNPs@PEG@HSA-TS265, 
respectively. AuNPs containing the compound TS265 showed to be promising for the treatment 
of the three tested types of cancer, having the ability to reduce the required doses of the 
compound in which the cell viability decreases in 50 %. Regarding AuNPs functionalised with 
the compound TS262, only the AuNPs@PEG@HSA-TS262 showed to be promising in 
HCT116. 
Keywords: bioconjugation, cancer cells, cytotoxicity, drug delivery, drug nanocarriers, gold 
nanoparticles 
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SYMBOLS AND NOTATIONS 
% (m/v) Mass/volume percentage 
% (v/v) Volume/volume percentage 
A549 Human lung carcinoma cell line (non-small cell lung cancer) 
AuNPs  Gold nanoparticles 
BSA Bovine Serum Albumin 
CCR Complete Culture medium Recipe  
Da Dalton 
DLS Dynamic Light Scattering 
DMEM  Dulbecco’s Modified Eagle Medium 
EDC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
EGFR Epidermal Growth Factor Receptor 
FBS Fetal Bovine Serum  
H1975 Human lung adenocarcinoma cell line (non-small cell lung cancer) 
HAuCl4 Chloroauric acid 
HCl  Hydrochloride acid 
HCT116  Human colorectal carcinoma cell line 
HNO3 Nitric acid 
HSA Human Serum Albumin 
IARC International Agency for Research on Cancer  
IC50 Concentration of a drug at which cell viability decreases in 50 % in relation to the 
control  
ICP-MS Inductively Coupled Plasma Mass Spectrometry 
MCF-10A Healthy human cell line from mammary gland 
MES 2-(N-morpholino)ethanesulfonic acid 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium 
MW Molecular Weight 
Na2HPO4 Sodium phosphate dibasic 
NaCl Sodium chloride 
NaH2PO4 Sodium phosphate monobasic 
nm Nanometres 
PEG Polyethylene glycol 
Phendione 1,10-phenanthroline-5,6-dione 
PMS Phenazine methosulfate 
ROS Reactive Oxygen Species 
rpm Rotations per minute 
RPMI 1640 Roswell Park Memorial Institute culture medium  
RT Room Temperature 
SEM Standard Error of the Mean 
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SPR Surface Plasmon Resonance 
Sulfo-NHS  N-hydroxysulfosuccinimide 
TEM Transmission Electron Microscopy 
TS262 [Zn(phendione)2]Cl2 
TS265 [Co(phendione)2(H2O)Cl]BF4 
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VEGF Vascular Endothelial Growth Factor 
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I. INTRODUCTION 
 
 1. CANCER 
 1.1 EPIDEMIOLOGY 
 
Cancer is the leading cause of death in developed countries and the second leading cause of 
death in developing countries. Non-healthy life styles such as poor diets, not practicing sports or 
smoking addiction, are increasing the incidence of cancer mainly in economically developing 
countries (Jemal et al. 2011). According to the International Agency for Research on Cancer 
(IARC) there were 14.1 million new cancer cases worldwide in 2012, of which 6 million occurred 
in developed countries. In the same year there were 2.9 million cancer deaths in developed 
countries in a total of 8.2 million worldwide. (GLOBOCAN 2012) 
In 2012, the most common cancer types in Portugal were breast, prostate, colorectal, lung, 
stomach and corpus uteri, causing a large number of cancer-associated deaths (GLOBOCAN 
2012). According to GLOBOCAN, five of these were also the most frequent cancer types 
worldwide. A representation of the incidence and mortality rates for each of these cancer types 
is shown at Figures I.1A and I.1B, expressing how this affects the population in Portugal and all 
over the world. 
  
Figure I.1 - Estimated incidence and mortality rates for the most common cancer types in Portugal (A) and 
worldwide (B), per 100 000 persons in 2012. All ages and both sexes considered. Adapted from 
GLOBOCAN, 2012. 
 
Estimated cancer incidence in the different continents, including both sexes and all ages, is 
represented at Figure I.2. 
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Figure I.2 – Percentage of incidence of new cancer cases by continent in 2012, excluding non-melanoma 
skin cancer. All ages and both sexes considered. Adapted from GLOBOCAN, 2012. 
 
It is expected that annual cancer cases will rise from 14 million in 2012 to 22 within the next two 
decades (WHO – World Health Organization). Indeed, it is foreseen that in 2030, 21.7 million of 
new cancer cases worldwide will be diagnosed, of which 61000 in Portugal (GLOBOCAN 2012). 
Powerful economic countries will possibly show a slight mortality rate decrease towards 2030 
due to early diagnosis and implementation of the newly developed cancer therapies (WHO).  
 
1.2 CARCINOGENESIS 
As seen in the previous section, cancer is a leading cause of death worldwide. This is a 
malignant disease defined as the rapid development of abnormal cells, their uncontrolled growth 
and spread, able to reach any part of the body via circulatory or lymphatic systems (WHO).  
Carcinogenesis is a multistep process (Hanahan & Weinberg 2000, Lewis 2004, Negrini et al. 
2010) in which normal cells undergo a progressive transformation to become malignant cells 
(Hanahan & Weinberg 2000). These steps reflect a series of genetic or epigenetic alterations 
that accumulate in genome (Lahtz & Pfeifer 2011, Negrini et al. 2013), causing genomic 
instability in almost all human cancers (Negrini et al. 2010). These alterations can be point 
mutations, small deletions or duplications, chromosomal rearrangements/translocations (Lahtz 
& Pfeifer 2011, Lewis 2004, Podlaha et al. 2012), or changes in DNA or histones by methylation 
or acetylation (Lal et al. 2013). Chromosomal instability is the major form of genomic instability 
observed in human malignant tumours (Negrini et al. 2010), and it was precisely the first type of 
genetic abnormality associated with cancer (Nowell & Hungerford 1960). It was observed that a 
translocation between chromosomes 9 and 22 (Philadelphia chromosome) was a critical step in 
chronic myeloid leukaemia patients. This translocation leads to the fusion of two protein 
kinases, the breakpoint cluster region (BCR) and Abelson leukaemia virus tyrosine kinase 
(ABL), which immortalises myeloid cells in the bone marrow, causing leukaemia (Lal et al. 
2013). 
Two classes of genes, proto-oncogenes and tumour-suppressor genes, play a key role in 
cancer induction. These genes encode proteins that help to control cell growth and proliferation; 
Europe -
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loss of function of tumour-suppressors genes by inactivating mutations and/or the activation of 
proto-oncogenes by gain-of-function are strongly involved in the development of genomic 
instability in the cells, contributing to the development of cancer (Chow 2010, Lewis 2004, Yang 
et al. 2007). Mutations in these genes directly affect cellular integrity leading to uncontrolled 
cells proliferation, escape from apoptosis, and to an increase of spontaneous mutation rate 
(Chow 2010, Negrini et al. 2010) (Figure I.3). DNA repair genes are a third class of genes 
associated with abnormal cells development (Curtin 2012, Goode et al. 2002, Lahtz & Pfeifer 
2011). The normal function of encoded proteins is to correct errors introduced in DNA by 
endogenous and/or exogenous mutagens (Goode et al. 2002). Thus, uncoordinated response 
of DNA repair genes leads to no DNA error correction, and consequently to carcinogenesis. 
Somatic mutations or epigenetic silencing of DNA repair genes are common in cancer (Curtin 
2012). The normal functions of tumour suppressor and DNA repair genes are related and 
probably at the same level of importance regarding normal cell division and growth (Lahtz & 
Pfeifer 2011).  
 
Figure I.3 – The accumulation of spontaneous mutations in genome, leading to cancer development. Cells 
acquire mutations in specific genes that control proliferation and all new generation of cells continue with 
these same mutations. More mutations can be acquired by these mutated cells leading to uncontrolled cell 
replication and cancer development (www.kintalk.org, accessed in March, 2014). 
Consequently, the phenotype of cancer cells differs from normal cells, and in 2000 Hanahan & 
Weinberg identified six hallmark alterations in cancer cell physiology: i) stimulation of their own 
growth; ii) resistance to growth-inhibitory signals; iii) escape from apoptosis; iv) continuous 
proliferation; v) stimulation the growth of blood vessel to supply nutrients to tumours 
(angiogenesis) and vi) invasion of local tissue and spreading to distant sites (metastasis) 
(Hanahan & Weinberg 2000) (Figure I.4). Metastases are the main cause of death by cancer 
(WHO), with near 1500 deaths per day (Seyfried & Huysentruyt 2013). This process consists in 
the spread of cancer cells from the primary tumour to other subjacent or non-subjacent parts of 
the body, resulting in malignant secondary tumours (Seyfried & Huysentruyt 2013). 
Angiogenesis, defined as the formation of new blood vessels from pre-existing vessels (Ichihara 
et al. 2011), is necessary to support tumour survival and proliferation, supplying oxygen and 
nutrients to malignant cells, providing the opportunity for them to enter in the circulatory system 
and disseminate (Cooper 2000).  
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Figure I.4 – Development steps of a malignant tumour and dissemination of cancer cells through the body 
via capillary and lymphatic vessels. An altered cell at genetic level yields an uncontrolled proliferative cell 
population, leading to the onset benign tumour and then to cancer. Cancer cells may invade blood and 
lymphatic vessels which lead to metastasis. Adapted from Cooper, 2000. 
In 2011, Hanahan & Weinberg updated the hallmarks of cancer and two new hallmark 
capabilities were included: reprogramming of energy metabolism and evading immune 
destruction (Hanahan & Weinberg 2011). 
1.3 RISK FACTORS 
Cancer result from genomic instability, but only 5 % of cancer cases are caused by internal 
factors, such as inherited mutations, defects in hormones or in immune system. Almost 95 % of 
cancer cases are caused by multiple mutations that result from population lifestyle and 
environment (Anand et al. 2008). Thus, some risk factors could be avoided, such as tobacco, 
alcohol abuse, poor diet, obesity or sedentary lifestyle, in order to not enhance the development 
of several cancer types (Anand et al. 2008, Irigaray et al. 2007). Although tobacco addiction in 
men has decreased significantly in several developed countries, it has increased progressively 
in women, remaining the main cause of cancer deaths (Irigaray et al. 2007). Tobacco contains 
at least 50 carcinogens (Anand et al. 2008), and besides lung cancer, is a risk factor for 
oesophagus, stomach, liver, bladder, kidney, cervical cancers and myeloid leukaemia (Anand et 
al. 2008, Irigaray et al. 2007). Environmental pollution, radiation and infectious microorganisms 
have also been implicated as causes of developing cancer. For instance, chronic infections 
caused by Human Papilloma Virus represent the main risk factor for cervix cancer development, 
and could also leading to carcinogenesis in vulva, vagina (Forman et al. 2012, Nygård et al. 
2014), penis or anus (Forman et al. 2012). The second leading cause of cancer death is the 
development of malignant tumours in stomach (Selgrad et al. 2012), which also have a chronic 
infection as the main risk factor, caused by Helicobacter pylori (Selgrad et al. 2012, Wroblewski 
et al. 2010).  
If cancer is early detected, a significant percentage of people can be cured by different cancer 
therapeutics (WHO). 
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 1.4 THERAPEUTICS 
The most common anticancer therapies consist of surgery, chemotherapy and radiotherapy, 
taken as conventional treatments by health care professionals (Irish Cancer Society, 2013). 
More recently emerged other types of cancer treatment such as the targeted therapy, 
photodynamic therapy, immunotherapy, or treatment by hyperthermia (American Cancer 
Society, 2013). The applied therapy depends on the type and stage of cancer. For instance, 
surgery and radiotherapy are more suitable for treating localised tumours, whereas 
chemotherapy is principally used when cancer cells spread outside their local of origin (Gordon 
& Nelson 2012). As a standard treatment and at different times, chemotherapy and radiotherapy 
could be also applied after malignant tumour removal by medical surgery (Cao et al. 2014).  
 1.4.1 CHEMOTHERAPY 
Chemotherapy is defined by the use of one (monotherapy) or more therapeutic drugs 
(combined therapy) for cancer treatment (Cao et al. 2014). This type of therapy is in continuous 
development since the first drug was discovered, nitrogen mustard, by Louis Goodman and 
Alfred Gilman in 1942. Nitrogen mustard demonstrated for the first time the induction of tumour 
regression by chemotherapy in a patient with non-Hodgkin’s lymphoma (Chabner & Jr 2005). 
Since then, research interest in anticancer drugs has increased and a significant number of 
these agents resulted in systemic therapeutics that cure or improve survival for certain cancer 
types (Gordon & Nelson 2012). The anticancer drugs should have a long half-life, high toxicity in 
cancer cells at biologically effective doses and should present high specificity for cancer cells 
(Chabner & Jr 2005). DNA-damaging drugs have been considered as the more advantageous 
in this process, causing cell cycle arrest and cell death (Helleday et al. 2008).  
The major problems in chemotherapy are the low specificity of drugs for cancer cells, the 
serious toxic side effects, such as bone marrow suppression, mucositis and alopecia (Cao et al. 
2014), and the ability of these abnormal cells to acquire resistance to anticancer drugs (Gordon 
& Nelson 2012). Drug resistance is precisely the main cause of treatment failure in metastatic 
cancer cases (Gordon & Nelson 2012, Hadjiandreou & Mitsis 2013, Longley & Johnston 2005), 
resulting from genetic mutations that may be intrinsic, reversible and dose-dependent or 
acquired during treatment (Hadjiandreou & Mitsis 2013). 
Multidisciplinary researchers are required and collaborate together looking for more effective 
anticancer drugs, and ways to ensure their success in cancer treatment (Chabner & Jr 2005, Lal 
et al. 2013). Considering the knowledge on human cancer biology (Chabner & Jr 2005) and on 
anticancer drugs, the possibility of a better and personalised cancer therapy to each patient, 
depending on cancer type, is highly increasing (Lal et al. 2013, Longley & Johnston 2005). 
Targeted therapies strongly contribute for this revolution in cancer treatment. The response of 
cancer cells to chemotherapy can be modulated by this type of therapeutics, which are actually 
competing against drug resistance (Longley & Johnston 2005). The specificity of targeted 
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therapies to cancer cells is much higher, with fewer toxic effects on healthy cells (American 
Cancer Society, 2013). This topic is discussed in more detail in section I.2.1.  
With the emergence of several new anticancer compounds, the organisation of chemotherapy 
drugs into classes became essential. Drugs are associated with each other considering their 
pathways and targets, their chemical structure and their activity when coupled with other drugs. 
According to American Cancer Society, chemotherapy drugs can be classified as alkylating 
agents, anti-metabolites, anti-tumour antibiotics, topoisomerase inhibitors, mitotic inhibitors, 
corticosteroids and miscellaneous. For instance, alkylating agents and anti-tumour antibiotics 
are both not phase-specific, i.e. act in all phases of the cell cycle, however alkylating agents 
work by damaging DNA whereas the anti-tumour antibiotics work by interfering with enzymes 
involved in DNA replication, dividing them into different classes (American Cancer Society, 
2013).  
 1.4.1.1 METAL COMPLEXES 
A metal complex is defined by a central metal atom surrounded by a set of ligands. These 
ligands behave as Lewis bases, in which the atoms that form the bond to the central atom are 
named the electron donor atoms. The metal ion behaves as a Lewis acid in the complex, being 
the electron acceptor atom in bond formation (Atkins et al. 2010). Metal complexes are 
incessantly suggested as alternative drugs to current anticancer therapeutics. These complexes 
generally act as pro-drugs, which are modified by ligand exchange and redox processes before 
achieving the target site (Romero-Canelón & Sadler 2013).  
The great interest in metal complexes as potential anticancer agents has increased since the 
discovery of biological activity of cisplatin [cis-diaminedichloroplatinum(II)] (Bharti & Singh 2009, 
Bruijnincx & Sadler 2008, Silva et al. 2013b). The mechanism of action of cisplatin is due to the 
formation of drug-DNA adducts, which interfere with replication and transcription processes, 
triggering cell cycle arrest and consequently apoptosis (Macciò & Madeddu 2013, Schmitt et al. 
2012). This metallic drug is classified as an alkylating agent (American Cancer Society, 2013) 
and is the most remarkable chemotherapeutic agent that has been used in clinical medicine 
(Bharti & Singh 2009). As the majority of anticancer drugs, the use of cisplatin is restricted in 
cancer treatment due to dose-dependent toxic side effects, severe systemic toxicity and 
inherent or acquired drug resistance (Bruijnincx & Sadler 2008). This triggered the emergence 
of many other metal complexes (Martins et al. 2014a, Frezza et al. 2010) containing zinc, 
copper, gold (Frezza et al. 2010), ruthenium, arsenic, titanium, silver or rhodium as metal ions, 
with promising potential as anticancer drugs, having analogous or distinct mechanisms of action 
than cisplatin (Bharti & Singh 2009), such as the anti-proliferative activity against cancer cells or 
the inhibition of certain enzymes (Gianferrara et al. 2009).  
Metal complexes provide a highly versatile platform for drug design due to their broad spectrum 
of coordination numbers and geometries, thermodynamic and kinetic characteristics 
 
7 
 
(e.g. strengths of metal-ligand bonds, redox potential or rates of ligand exchange (Romero-
Canelón & Sadler 2013)), and intrinsic properties such as the type of metallic ion and the 
flexibility of containing several types of ligands (Bruijnincx & Sadler 2008). Take into account the 
classical chemotherapy, non-covalent interactions are the most frequently by metallic drugs, 
involving the intercalation of planar aromatic molecules between the base pairs of DNA, 
triggering cell death. Other mechanisms as the intercalation with RNA, cleavage of DNA strands 
and modifications of cell membrane functions have also been described regarding anticancer 
metallopharmaceuticals (Bharti & Singh 2009). 
 
 1.4.1.1.1 TS262 AND TS265  
The [Zn(Phendione)2]Cl2 (TS262) and [CoCl(H2O)(Phendione)2]BF4 (TS265) complexes 
(Figures I.5A and I.5B, respectively) are two water-soluble metal-based compounds with 
cytotoxic activity against cancer cells (Luís et al. 2014, Silva et al. 2013a,b). For development 
studies and clinical progress concerning promising anticancer drugs, aqueous stability is a 
prerequisite (Pizarro et al. 2010). These anti-proliferative agents are both mononuclear 
compounds with zinc and cobalt as central metal atom, respectively (Silva et al. 2013b). TS262 
is a homoleptic complex, meaning that all ligands in the complex are identical, which is in this 
case two 1,10-phenanthroline-5,6-dione (phendione) (Figure I.5C) bound to zinc(II). Relative to 
TS265, there are three different ligands, meaning that the complex is heteroleptic. Beyond the 
bidentate ligand phendione, there are a chlorine atom and a water molecule bound to cobalt(II) 
(Silva et al. 2013b).  
 
 
 
                      (C) 
 
Figure I.5 – Chemical structure of the two anticancer metal complexes: (A) TS262 ([Zn(phendione)2]Cl2) 
and (B) TS265 ([Co(phendione)2(H2O)Cl]BF4); and the structure of (C) 1,10-phenanthroline-5,6-dione 
(phendione), the ligand present in both TS262 and TS265 compounds (Silva et al. 2013b). 
The anti-proliferative activity of TS262 and TS265 has been previously tested in HCT116 
human colorectal carcinoma cell line and in healthy human fibroblast cell line and their IC50 has 
been estimated (Silva et al. 2013b). IC50 is a quantitative measure that consists in the 
(A)                                                                (B) 
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concentration of a drug at which cell viability decreases for 50 % in relation to the control, i.e. 
untreated cells. The in vitro anti-proliferative activities of TS262 and TS265 are lower in healthy 
human fibroblasts cell line (0.62 μM and 0.60 μM, respectively) than in HCT116 tumour cell line 
(0.217 ± 0.022 μM and 0.206 ± 0.023 μM, respectively), indicative of their slightly higher 
specificity for this type of cancer cells (Silva et al. 2013b). These estimated IC50 values in 
HCT116 tumour cell line are about 70 times lower than the IC50 values for the commonly used 
chemotherapeutic drug cisplatin (15.2 ± 0.55 μM), tested under the same conditions (Silva et al. 
2013b). Other metal complexes bearing the ligand phendione with copper(II), silver(I) or 
manganese(II) as central metal atom have also shown promising anticancer potential even 
better than cisplatin against cancer cell lines (Bharti & Singh 2009). Moreover, anti-proliferative 
activity of TS265 has been also previously tested in healthy human cell line from mammary 
gland (MCF-10A) in which cell viability decreases only about 20 % at 1 μM of TS265, 
demonstrating once again the higher specificity for cancer cells than healthy cells (Luís et al. 
2014). These positive features make it necessary a greater exploration of these metallodrugs as 
new potential compounds for cancer treatment.  
TS265 complex has been more extensively studied than TS262. In recent studies was 
demonstrated that the anti-proliferative activity of TS265 is due to cell cycle arrest in S-phase 
and subsequent apoptosis (Luís et al. 2014, Silva et al. 2013a). Proteomic analysis of HCT116 
cancer cells exposed to TS265 was also performed and it was observed the up-regulation of 
oxidative stress-related enzymes superoxide dismutase (SODC) and peroxiredoxine 2 
(PRDX2), and also of stratifin (14-3-3 protein Ϭ) and proliferation-associated protein 2G4 
(PA2G4). An increased level of reactive oxygen species (ROS) was seen in the cells exposed at 
the same conditions, and the over-expression of SODC and PRDX2 are probably related with 
this fact because their function is precisely to protect cells from ROS. The formation of such 
ROS might arise from redox properties of TS265 complex. The down-regulation of 
translationally-controlled tumour protein (TCTP), heat shock protein beta 1 (HSPB1), 
endoplasmin (HSP90B1), tropomyosin 3 (TPM3), ezrin (EXRI) and cytoskeleton-related 
proteins, that are usually up-regulated in untreated cancer cells, was also observed in HCT116 
cancer cells exposed to TS265 (Silva et al. 2013a). According to these results, the compound 
exhibits a great potential in the regulation of proteins that are typically deregulated in cancer 
cells. In order to study the interaction of TS265 with biological components circulating in blood 
of a living organism, the interaction between TS265 and human serum albumin (HSA) was 
studied, and results demonstrated a strong and specific interaction involving one binding site, 
near to Trp-214 (Luís et al. 2014). This suggests that the complex can be effectively transported 
by the most abundant protein in human blood plasma, a great influence for their distribution in 
the body. In fact, is reported the ability of complexes bearing the ligand phendione to bind 
covalently to proteins. The quinone moiety of phendione can behave as a nucleophile and react 
with the nucleophilic component in the side chains of lysine and arginine, i.e. the amino group 
and guanidine group (Yokoyama et al. 2006).  
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Similarly to TS262 complex, other metal compounds containing zinc as central metal atom have 
demonstrated to be potential non-classical anticancer agents, with new modes of action and 
new cellular targets compared to the classical chemotherapeutic drugs (Sanz Mendiguchia et al. 
2013). It is believed that zinc is an important cytotoxic/tumour suppressor agent in several 
cancers since it was observed that the amount of cellular zinc was clearly lower (~60-80 %) in 
prostate cells cancer than in healthy or benign prostate cells. This relationship was proved for 
other types of cancer such as hepatocellular carcinoma, pancreatic adenocarcinoma, ovarian, 
oesophageal or colon cancers. The role of zinc on the inhibition of synthetic and energetic 
requirements for the malignant process, on the promotion of apoptosis and cell cycle arrest, and 
on the inhibition of invasion and migration prevents cancer development or, if cancer exist, the 
advancement to metastasis (Costello & Franklin 2012). 
 2. NANOMEDICINE 
Nanomedicine is defined as the application of bionanotechnology to medicine (Yadav et al. 
2011). In turn, bionanotechnology is defined as a fusion between two of the most promising 
technologies: biotechnology and nanotechnology. The objective of nanotechnology is the 
design, development and application of materials and tools at the nanoscale, i.e. ranging from 
1 to 100 nm, whereas biotechnology uses the knowledge and techniques of biology to develop 
products and services based on molecular, genetic and cellular processes (Fakruddin et al. 
2012). A broad range of areas are involved in this field, such as engineering, biology, medicine 
and chemistry, which are working together towards progress of bionanotechnology (Jabir et al. 
2012). Bionanotechnology materials provide useful and direct applications in life sciences by 
sharing the same length scale of a great part of biomolecules (Kim et al. 2013) (Figure I.6).  
 
Figure I.6 – Multiple-scale of living biological materials and systems. Biomolecules of living systems and 
nanoscale materials share the same length scale providing an interface and direct applications of these 
materials in life sciences. Adapted from Kim et al. 2013. 
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Nanoparticles are the main focus in nanomedicine, be it for diagnostics or therapy, including 
selective targeting and molecular imaging for biomedical applications (Fakruddin et al. 2012, 
Parveen et al. 2012). 
 
2.1 NANOPARTICULATE DRUG DELIVERY SYSTEMS IN CANCER 
TREATMENT 
The application of functionalised nanoparticles, specifically in cancer biology, is a rapidly 
growing field, contributing to the development of methods for early detection of cancer cells 
(nanodiagnostics), and for the development of novel therapeutic approaches that enhances 
selectivity and efficacy of cancer therapy (Conde et al. 2014). In fact, besides cellular 
mechanisms of drug resistance, other of the main limitations of current chemotherapeutics is 
the inability to reach the target site, cell, tissue or organ, of therapeutic need (Martins et al. 
2014b). Thus, biocompatible nanoparticles take advantage of the pathological and physiological 
conditions of cancer tissues, such as increase metabolism, local pH, enhanced permeability of 
endothelia, etc (Fakruddin et al. 2012). These nanomedicines may overcome limitations of 
traditional approaches in overcoming lack of selective targeting, gaining acess to tumour cells 
by surpassing biological, biophysical and biomedical barriers (Jabir et al. 2012).  
The principle of targeted drug delivery system is the accumulation of drugs in the desired 
tissues, i.e. targeted site, reducing or eliminating deleterious side effects in healthy tissues 
(Silva et al. 2014c, Kumar et al. 2013a). Several types of nanoparticles, such as dendrimers, 
liposomes, carbon nanotubes, polymeric, ceramic and metallic nanoparticles are currently being 
used as targeted drug delivery systems for cancer treatment (Alexis et al. 2010, Wang et al. 
2012). Therapeutic agents are encapsulated, entrapped, attached or dissolved in those 
nanoparticle-based systems and the targeted strategies for drug delivery may be achieved via 
passive or active mechanisms (Chakraborty et al. 2013). Passive strategy takes advantage of 
the pathophysiological features of diseased tissues that may be altered through the enhanced 
permeability and retention (EPR) effect. The leaky tumour blood vessels allow the circulating 
nanoparticles to easily accumulate in cancer tissues (Parveen et al. 2012). In turn, active 
targeting mechanisms are used to direct nanocarriers to specific sites utilising targeting moieties 
such as antibodies, lipoproteins, hormones, charged molecules or nucleic acids (Torchilin 
2010). Thus, a better and personalised cancer treatment for each patient (previously discussed 
in section I.1.3), has started to be possible with the emergence of these nanoparticle-based 
drug delivery systems, improving the safety and efficacy of chemotherapeutics. Additionally to 
the advantages of deliver the drug at the desired site, nanocarriers systems fill other limitations 
of conventional chemotherapeutic agents, such as the administration of both hydrophilic and 
hydrophobic substances, decreased systemic toxicity and slower compound degradation, 
resulting in larger half-lives and consequently lower dosage (Martins et al. 2014b).  
Despite intense research on biocompatible nanoparticles for cancer therapeutics, there are only 
a few nanoparticle systems for drug delivery approved by US Food and Drug Administration and 
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European Medicines Agency in the market: Caelyx®, Myocet®, DaunoXome®, DepoCyt®, 
Abraxane®, Genexol-PM® and Oncospar® (Egusquiaguirre et al. 2012). 
 2.1.1 GOLD NANOPARTICLES (AuNPs) 
Among metallic nanoparticles available for medical applications, AuNPs are the most 
synthesised and explored nanocarriers (Martins et al. 2014b). AuNPs usually present 
themselves in colloidal suspension whose application and use dates back to ancient Rome, 
when they were used in stained glass for decorative purposes. However, the modern era of 
AuNPs began over 150 years ago when Michael Faraday observed that colloidal gold had 
different properties from bulk gold (Giljohann et al. 2010). In the 1950s, AuNPs began to be 
used in immunodiagnostics and histopathology, and were described as anti-neoplastic agents 
(Kumar et al. 2013b). In recent years there has been an increased interest in the attractive 
properties of colloidal gold, leading to new exciting developments with great potential in biology 
and medicine (Thompson 2007), being actually one of the most important candidates in the field 
of cancer therapy (Kumar et al. 2013b). 
AuNPs present amazing optical properties derived from Surface Plasmon Resonance (SPR), 
resulting in high absorption and light scattering. Also their high chemical stability, low toxicity 
and biocompatibility make them a versatile vehicle, especially for drug delivery and imaging 
(Kumar et al. 2013a). The successful utilisation of AuNPs in biomedical assays is also 
dependent on the availability of methods to synthesise nanoparticles with controlled shape and 
size (1 to 150 nm in diameter). Perhaps the most used AuNPs of drug delivery systems are 
spherical with sizes between 20 and 60 nm, considered the therapeutic window for these 
nanovectors (Tiwari et al. 2011a) (Figure I.7). Colloidal solutions of gold nanospheres are 
typically red with the SPR band at ca. 520 nm, which depends from size alterations or refractive 
index of the surrounding media (Baptista et al. 2008). 
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Figure I.7 – AuNPs of various size and shape with potential applications in biomedicine. Small (a) and 
large (b) nanospheres, (c) nanorods, (d) sharpened nanorods, (e) nanoshells, (f) nanocages/frames, (g) 
hollow nanospheres, (h) tetrahedra/octahedra/cubes/icosahedra, (i) rhombic dodecahedra, (j) octahedra, 
(k) concave nanocubes, (l) tetrahexahedra, (m) rhombic dodecahedra, (n) obtuse triangular bipyramids, 
(o) trisoctahedra, and (p) nanoprisms (Dreaden et al. 2012). 
AuNPs can be easily modified with multiple surface moieties (e.g. PEG, BSA, oligo or 
polypeptides, oligonucleotides, antisense or sense RNA molecules, antibodies, cell surface 
receptors (Tiwari et al. 2011a)) and/or chemotherapeutic agents (Trivedi et al. 2012), in which 
the high surface-to-volume ratio offer an efficient drug loading capability – for a comprehensive 
review, please refer to Cabral & Baptista 2013, and references therein. The exceptionally optical 
properties arising from the SPR of AuNPs are affected by all of those modifications, and are 
reflected in wavelength alterations (Tiwari et al. 2011a) due to their higher sensitivity in optical 
detection methods (Baptista et al. 2008).  
 2.1.1.1 SYNTHESIS 
The first controlled synthesis of gold nanospheres was reported in 1951 by Turkevich et al. via 
the sodium citrate method in which monodisperse AuNPs (10-20 nm in diameter) were 
obtained. Later, Frens et al. optimised that method, and became the widely used method to 
produce AuNPs (Ladj et al. 2013). To synthesise AuNPs through this method, an aqueous 
solution of chloroauric acid (HAuCl4) is used in which the Au
3+
 ions are reduced to Au
0
 by 
sodium citrate (Cai et al. 2008, Ladj et al. 2013). The ratio citrate/gold is the key to synthesise 
the particles with the desired size, wherein larger amounts of citrate promote the production of 
smaller gold nanospheres (Cai et al. 2008). The citrate has also the function of stabilise the 
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colloidal solution of gold, protecting AuNPs from aggregation (Ladj et al. 2013). Interestingly, 
AuNPs capped/stabilised with citrate ions are very convenient to be properly functionalised for 
biological applications due to the ease of binding molecules of interest directly to citrate ions or 
due to the ease replacement by other capping agents, e.g. thiolated capping agents (Baptista et 
al. 2008). 
During the last few years many other interesting methods and techniques has been described 
for the synthesis of AuNPs such as microwave power, self reduction or the synthesis from 
microorganisms and plant extracts (Ladj et al. 2013). 
 2.1.1.2 FUNCTIONALISATION  
Functionalisation of AuNPs is essential for their efficacy in drug deliver, namely towards 
biocompatibility (DeLong et al. 2010) and long-term stability in biological fluids (Rahme et al. 
2013). AuNPs should preserve their unique properties such as SPR absorption or light 
scattering with their functionalisation, and the bonded molecules should retain its biological 
recognition properties (DeLong et al. 2010). Molecules containing chemical functional groups, 
such as a polyethylene glycol (PEG) that holds a thiol and a carboxyl group, are normally used 
to stabilise AuNPs. One end of these molecules is strongly adsorbed on the gold surface by the 
thiol group. The other end stabilises the water-soluble nanoparticles by electrostatic repulsion of 
carboxylic acid or can be used for the conjugation of biomolecules to the AuNPs (DeLong et al. 
2010) (Figure I.8). Please refer to Cabral & Baptista 2013 for additional insights. 
 
Figure I.8 – Adsorption of PEG molecules on an AuNP surface. One end of these molecules contains a 
thiol which is adsorbed on the gold surface, and the other end holds a carboxyl group that is facing toward 
the solution. This type of carbonate chains stabilise AuNPs against aggregation and allow their 
functionalisation with other biomolecules and/or chemotherapeutics (DeLong et al. 2010). 
PEGylation, i.e. nanoparticles coated with PEG, is one of the mainly used methods that allow 
the stabilisation and functionalisation of AuNPs (Silva et al. 2014c, Tiwari et al. 2011b). The use 
of PEG enable the nanoparticles do not aggregate even under extreme pH or ionic strength 
conditions (DeLong et al. 2010). Furthermore, PEGylation has shown many other attractive 
properties such as the reduction of immunogenic response and the prevention of non-specific 
protein adsorption  (Naahidi et al. 2013), increasing the stabilisation of AuNPs in biological 
environment, and also increasing the targeting and drug accumulation (Dreaden et al. 2012). 
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Regarding drug delivery systems, PEGylated nanoparticles have shown to slower 
chemotherapeutic agent degradation, thus extending their half-lives and decreasing the dosage 
(Naahidi et al. 2013).  
There are various methods available for the conjugation of biofunctional molecules to AuNPs, 
and both physical and chemical mechanisms have been utilised. Among physical mechanisms, 
electrostatic interactions between a nanoparticle surface and an existing thiol group in the 
biomolecule are the most commonly, replacing some of the original stabiliser molecule (DeLong 
et al. 2010). Concerning chemical mechanisms, the most common method for AuNPs 
functionalisation consists in the covalent binding of amino groups on the biomolecules with free 
carboxyl groups at the end of the stabiliser molecule by using 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC)/N-hydroxysulfosuccinimide (sulfo-NHS) coupling reaction 
(Figure I.9). EDC is a widely used carbodiimide that catalyses the reaction, and in turn, 
sulfo-NHS is used to stabilise the active intermediates by the formation of active ester functional 
groups with carboxylates (Bartczak & Kanaras 2011). 
 
Figure I.9 – Scheme of chemical mechanism for the conjugation of biological molecules (BM) containing 
an amino group (-NH2) to free carboxyl groups at the end of the stabiliser molecule on AuNPs, by 
EDC/sulfo-NHS mediated reaction (DeLong et al. 2010).   
 2.1.1.3 AuNPs-BASED DRUG DELIVERY SYSTEMS FOR CANCER TREATMENT       
Delivery of AuNPs into cells typically implies their adsorption onto cell surface followed by their 
internalisation, in which cell-penetrating peptides or cell surface antibodies coating AuNPs may 
facilitate their internalisation through endocytosis (Figure I.10). Endocytosis is the most 
prevalent mechanism used by cells to internalise this type of particles, however have been 
reported other mechanisms. Besides endocytosis, the internalisation of anionic AuNPs may also 
occur by forming an interface with the cell membrane when nanoparticles are coated with serum 
proteins, which are adsorbed by electrostatic and hydrophobic interactions. In turn, cationic 
AuNPs usually bind to negatively charged groups on the cell membrane and cross the plasma 
membrane. Despite those positively charged nanoparticles are the most effective in crossing 
cell membrane, show higher cytotoxicity than anionic or neutral AuNPs (Voliani et al. 2012). 
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Figure I.10 – Representative scheme of the internalisation of AuNPs into cells through receptor-mediator 
endocytosis. In this representative case, AuNPs ligands bind to cell surface receptors and together are 
taken into the cell via endosomes. In this compartment, receptors and AuNPs ligands dissociate and follow 
two different pathways: cell surface receptors are recycled and AuNPs follow to lysosome, where every 
biofunctional molecules are degraded. By exocytosis, naked AuNPs are excluded from intracellular matrix. 
Adapted from Tran & Webster 2013.  
AuNPs are functionalised with specific molecules to detect some stimulus (e.g. binding to a cell 
surface receptor, ionic concentration or pH media changes) in order to respond at once by 
releasing cargo, and consequently the drug, into cells or tissue in vitro and in vivo (Dreaden et 
al. 2012). Chemotherapeutic agents can be loaded into the cells by AuNPs through 
non-covalent interactions in which no structural modification is needed for drug delivery (Trivedi 
et al. 2012), in the case of hydrophobic drugs, or through covalent binding by coupling the 
terminal groups of the capping agents or the gold surface by affinity of thiols (Dreaden et al. 
2012). In addition, and to address their success, these drug delivery nanosystems must be 
functionalised in order to carry the drug to the right place at the right time, overcoming all 
biological barriers (Kumar et al. 2013a).  
The first formulation of AuNPs for cancer treatment in early-phase clinical trials is Aurimune™ 
(CYT-6091). This drug delivery system consists in 27 nm PEGylated nanoparticles bound to 
recombinant human tumour necrosis factor alpha (TNF-α), an anticancer agent, and has 
actually the phase I completed in clinical trials. Preclinical and clinical studies demonstrated the 
safety in humans through blood stream avoiding immune system, and a successful targeted 
delivery of TNF-α in solid cancers, at levels required for a biological response (CytImmune 
Sciences, Rockville).  
Several formulations concerning AuNPs-based drug delivery systems for cancer treatment are 
being studied. Brown et al. developed an AuNPs-based system that improves the delivery and 
efficacy of oxaliplatin in cancer cells. They grafted oxaliplatin onto PEGylated AuNPs, showing 
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enhanced cytotoxicity in lung and colorectal cancer cell lines, and also an unusual ability to 
penetrate the nucleus in the lung cancer cells (Brown et al. 2010). Oxaliplatin, like the highly 
effective chemotherapeutic drug cisplatin, is known to be dose-dependent and represent 
dose-limiting severe side effects, like neurotoxicity, nausea and vomiting (Brown et al. 2010).  
Thus, in order to avoid compromising the therapeutic efficacy, it is important to develop of such 
nanosystems, avoiding the non-specific attack of all rapidly proliferating cells. Heo et al. also 
formulated a PEGylated AuNPs-based nanosystem that carries paclitaxel (Heo et al. 2012), one 
of the most effective chemotherapeutic drug, used for the treatment of several types of cancer 
(Ma & Mumper 2013). This drug delivery nanosystem demonstrated higher cytotoxicity in cancer 
cell lines than in normal cell lines, increasing their potential as an actively targeted anticancer 
drug (Heo et al. 2012). Also doxorubicin were tethered through disulfide linkage onto PEGylated 
AuNPs, and showed a significant inhibition of the growth of multidrug-resistant cancer cells in 
vitro. Doxorubicin is a topoisomerase inhibitor and an anthracycline antibiotic used for treating 
various types of cancer. However, the frequent clinical use of this chemotherapeutic agent often 
causes drug resistance and/or cardiotoxicity, highlighting the potential of these AuNPs-based 
drug delivery vehicles which overcome drug resistance in cancer treatment (Gu et al. 2012). 
There are some formulations that demonstrate the advantage of using BSA on AuNPs for 
carrying drugs to the site of the disease. Murawala et al. have studied the effect of methotrexate 
on BSA capped AuNPs. They demonstrated that the functionalised AuNPs have higher 
cytotoxicity on breast cancer cell line compared with an equivalent dose of free methotrexate. 
The preferential uptake of nanoparticles by cancer cells was attributed to the presence of BSA 
on AuNPs that acts as a source of nutrient and energy for these malignant cells (Murawala et al. 
2014). Methotrexate is an antimetabolite chemotherapeutic drug and prevents cells from using 
folate to make DNA and RNA, stopping the growth of cancer cells (American Cancer Society, 
2011). AuNPs functionalised with BSA have been recently stated as one of the best drug 
delivery vehicle for cancer treatment (Khullar et al. 2012). Although many studies based on 
BSA-capped AuNPs have been reported, only a small number are reported with HSA on AuNPs 
surface. 
The in vivo cytotoxicity of AuNPs functionalised with BSA or PEG molecules, with a thiol at one 
end and a carboxylic group at the other end (HS-PEG-COOH), were tested in mouse after 
intravenous injections. The study demonstrates that there was no statistical significance in the 
difference between the groups that receive the highest doses of AuNPs@BSA or AuNPs@PEG 
and the control group, i.e. untreated with nanoparticles. The mice in all groups were healthy, 
and were demonstrated by TEM images that the functionalised nanoparticles just accumulate in 
liver lysosomes. There was also no uptake in the nucleus, mitochondria or Golgi complex in liver 
cells, or in other cell types (Lien Nghiem et al. 2012). It was the first results of in vivo cytotoxicity 
studies concerning functionalised AuNPs with PEG or BSA, revealing two potential non-toxic 
vehicles for drug delivery. 
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 3. OBJECTIVES 
Numerous drug delivery nanosystems have been developed to improve the efficacy of 
chemotherapeutics and to target the drug to the desired cells, tissues or organs. The main goal 
of this work was to develop optimised AuNPs-based vehicles for drug delivery that could 
provide a solution to the afore mentioned problems. To achieve this goal several intermediate 
goals were set: 
i) Cytotoxicity assays with free TS262 and TS265 in A549 and H1975 cancer cell 
lines, and the determination of the relative IC50 of the compounds in these cell lines; 
ii) Synthesis of AuNPs and subsequent functionalisation with PEG via Au-S covalent 
bond 
iii) AuNPs@PEG functionalisation with BSA and HSA to obtain AuNPs@PEG@BSA 
and AuNPs@PEG@HSA; 
iv) Assembly of AuNPs@PEG@BSA-TS262, AuNPs@PEG@BSA-TS265, 
AuNPs@PEG@HSA-TS262 and AuNPs@PEG@HSA-TS265; 
v) Physic-chemical characterisation of the AuNPs systems; 
vi) Cytotoxicity assays with AuNPs@PEG@BSA-TS262, AuNPs@PEG@BSA-TS265, 
AuNPs@PEG@HSA-TS262 and AuNPs@PEG@HSA-TS265 in HCT116, A549 
and H1975 cancer cell lines 
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II. MATERIALS AND METHODS 
1. METALLIC COMPOUNDS – TS262 AND TS265 
The metallic complexes, TS262 and TS265, used in the current work were synthesised at Area 
Departamental de Engenharia Química, ISEL, according to the methods described by Silva et 
al. 2013b. Stock solutions of TS262 and TS265 were prepared (10.1 mM and 23 mM, 
respectively) by dissolution in autoclaved milli-Q H2O (pH 7), and then aliquoted and stored at -
20ºC. The chemical formula and molecular weight of the compounds are described in Table II.1. 
Table II.1 – Required information to support the current work regarding compounds under 
consideration - TS262 and TS265. 
Compound Chemical Formula Molecular Weight (Da) Solvent 
TS262 ZnC24H12N4O4Cl2 617.9 Autoclaved milli-Q H2O 
TS265 CoC24H14N4O5BF4 619.6 Autoclaved milli-Q H2O 
 
2. CULTURE OF HUMAN CELL LINES 
HCT116 human colorectal carcinoma cells and A549 human lung carcinoma cells were grown 
in Dulbecco’s Modified Eagle’s Medium (DMEM) (DMEM, Invitrogen) supplemented with 
10 % (v/v) Fetal Bovine Serum (FBS) (FBS, Invitrogen) and 1 % (v/v) antibiotic/antimycotic 
solution (Pen-Strep+antimycotic: 10000 units/mL of penicillin, 10000 µg/mL of streptomycin and 
25 µg/mL of Fungizone® Antimycotic; Invitrogen), which is in conjunction nominated complete 
culture medium recipe (CCR). Cells were maintained in 75 cm
2
 culture flasks (BD Biosciences) 
at 37 ºC in a 99 % humidified atmosphere of 5 % (v/v) CO2 (CO2 Incubator Leec, UK).  
H1975 human lung adenocarcinoma cells was grown in RPMI (Roswell Park Memorial Institute) 
1640 medium (RPMI; Invitrogen) supplemented with 10 % (v/v) FBS and 1 % (v/v) 
antibiotic/antimycotic solution (Pen-Strep+antimycotic: 10000 units/mL of penicillin, 10000 
µg/mL of streptomycin and 25 µg/mL of Fungizone® Antimycotic; Invitrogen), which is also 
nominated CCR. As well as the cell lines previously described, these cells were maintained in 
75 cm
2
 BD flasks at 37 ºC in a 99 % humidified atmosphere of 5 % (v/v) CO2.  
At approximately 80 % of confluence, cell culture medium was renewed. For that, culture 
medium was aspired, added 4 ml trypsin (Invitrogen) and maintained for 5 minutes at 37 ºC in a 
99 % humidified atmosphere of 5 % (v/v) CO2. After confirming loss of cells adherence using an 
inverted microscope (Nikon TMS), 4 ml of appropriated CCR was added to the BD flask 
containing the cells to neutralise the trypsin. The solution was removed to a BD Falcon tube (BD 
Biosciences) and centrifuged for 5 minutes, at 1500 g and 15 ºC in a centrifuge (Sigma 3-16K, 
UK). Pellet was resuspended in 2 mL of the appropriate CCR medium, in which 50 μL of this 
solution was added to a new 75 cm
2
 BD flask, contained 13 mL of CCR, and maintained in the 
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conditions previously described. The remaining cells suspension was used in the assays 
described in section II.3.2. 
3. CYTOTOXICITY STUDIES OF TS262 AND TS265 
3.1 CELL COUNT ASSAY BY TRYPAN BLUE 
Cell count was assessed by trypan blue exclusion assay. A solution containing 100 μL of 
0.4 % (m/v) trypan blue (Sigma), 350 μL of appropriate CCR to each culture and 50 μL of 
cellular suspension was placed on a haemocytometer (Hirschmann, Germany), and the number 
of viable cells was determined using an inverted microscope. After cell counting, cell density 
was determined according to Equation II.1: 
(II.1) 
𝑁𝑟.𝑜𝑓 𝑉𝑖𝑎𝑏𝑙𝑒 𝐶𝑒𝑙𝑙𝑠
𝑚𝑙
=
𝛴𝑁𝑟. 𝑜𝑓 𝑉𝑖𝑎𝑏𝑙𝑒 𝐶𝑒𝑙𝑙𝑠 𝑄𝑢𝑎𝑑𝑟𝑎𝑛𝑡𝑠 1 𝑡𝑜 4
4
. 104 𝑁𝑒𝑢𝑏𝑎𝑢𝑒𝑟 𝑐𝑕𝑎𝑚𝑏𝑒𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 𝑖𝑛 𝑚𝑚3 .𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝐹𝑎𝑐𝑡𝑜𝑟 
3.2 CELL SEEDING WITH TS265 AND TS262 
Following the determination of viable cells density, the cellular suspension obtained in 
section II.2 was diluted to 0.75 x 10
5
 cells/mL using the appropriated CCR. In a 96-well plate 
(Orange Scientific, Belgium) were seeded 7500 cells/well and incubated at 37 ºC in a 99 % 
humidified atmosphere of 5 % (v/v) CO2 for 24 hours. After this time, cells seeded were 
observed using an inverted microscope and their adherence were confirmed. CCR was 
removed from each well and replaced by (i) 100 μL of fresh culture medium, the negative 
control,  (ii) 100 μL of a range of concentrations of TS262 (0.1 – 40 μM), and (iii) 100 μL of a 
range of concentrations of TS265 (0.1 – 40 μM). The (ii) and (iii) solutions were prepared in 
fresh culture medium from the stock solutions of both compounds. All solutions were plating in 
triplicate. The 96-well plate was next incubated for 48 hours under the same conditions 
previously described.  
3.3 CELL VIABILITY BY MTS ASSAY 
After incubating the cells with the anticancer compounds for 48 hours (37 ºC in a 99 % 
humidified atmosphere of 5 % (v/v) CO2), the cytotoxicity assay assessed by 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and 
phenazine methosulfate (PMS) (CellTiter 96® Aqueous Non-Radioactive Cell Proliferation 
Assay, Promega, USA) was performed. Culture medium was removed from each well of the 
plate and replaced by 100 μL of complete MTS solution per well (100:20:1 ratio of CCR, MTS 
and PMS, respectively). The 96-well plate was incubated for 30 minutes at 37 ºC in a 99 % 
humidified atmosphere of 5 % (v/v) CO2.  
MTS/PMS assay is a colorimetric method used for the quantification of viable cells. Viable cells 
are able to reduce MTS into a formazan product that absorbs at 490 nm. The absorbance at this 
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wavelength was measured directly from 96-well plates in a microplate photometer (Infinite 
M200, Tecan, Switzerland), and cell viability was determined according to Equation II.2: 
(II.2) 
𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦  % =  
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑎𝑡 490 𝑛𝑚 (𝑠𝑎𝑚𝑝𝑙𝑒)
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑎𝑡 490 𝑛𝑚 (𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑎𝑣𝑒𝑟𝑎𝑔𝑒)
. 100 
 
The percentage of cell viability for each concentration was determined take into account three 
independent assays. 
3.4 RELATIVE IC50 
The relative IC50, i.e. the quantitative measure that consists in the concentration of a drug at 
which cell viability decreases in 50 % compared to the control, was determined by GraphPad 
Prism 6 program (GraphPad Software Inc., USA), take into account the three independent 
assays obtained in section II.3.3. 
4. SYNTHESIS OF AuNPs  
The colloidal solution of 14 nm AuNPs was prepared by the citrate reduction method, described 
by Lee and Meisel (Lee & Meisel 1982).  
All glass materials used for the synthesis of AuNPs were previously immersed in aqua regia - 
prepared by adding 3 parts of concentrated HCl (Sigma) to 1 part of concentrated HNO3 
(Sigma) - for at least 2 hours, and after that, vigorously washed with milli-Q H2O (18.2 MΩ.cm at 
25 °C). Thereafter, 250 mL of 1 mM HAuCl4 (Sigma, MW 393.83 Da) was brought to a boil while 
stirring, in a 500 mL round-bottom flask. When in reflux, 25 mL of 38.8 mM of sodium citrate 
(Sigma, MW 294.10 Da) was added and kept refluxing for 20 minutes with continuous stirring. 
After this time, the colloidal solution was cooled to room temperature (RT), keeping the 
continuous stirring, and transferred to an Erlenmeyer flask and stored away from light at RT.  
All solutions were prepared with milli-Q H2O.  
Hydrodynamic diameter of synthesised AuNPs was characterised by Transmission Electron 
Microscopy (TEM) and Dynamic Light Scattering (DLS), and their concentration determined by 
UV-Vis spectroscopy. 
5. FUNCTIONALISATION OF AuNPs 
5.1 AuNPs@PEG  
AuNPs were functionalised with a bifunctional polyethylene glycol (PEG) molecule (Iris 
BIOTECH, MW 458.57 Da) containing a thiol group at one end of the molecule and a carboxyl 
group at the other end - HS-EG(8)-COOH.  
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In order to obtain a complete saturation of the polymer on AuNPs, a range of concentrations 
(0 - 0.1 mg/mL) of PEG were tested with a fixed concentration of nanoparticles. For that, 
different volumes of PEG were added to solutions containing 10 nM of synthesised colloidal 
AuNPs, 0.028 % of Sodium Dodecyl Sulfate (SDS) (Sigma, MW 288.38 Da) and milli-Q H2O. 
These solutions were incubated for 16 hours while stirring in a GFL 3016 shaker at RT. 
Afterwards 16 hours incubation, all solutions were centrifuged at 14000 rpm for 30 minutes at 
4 ºC, for three times to remove excess of PEG, where supernatants were removed to new 
eppendorfs and replaced by milli-Q H2O. After obtaining all supernatants, those were also 
centrifuged at the same previously described conditions, and next thiolated chains of PEG 
present in these solutions were quantified by Ellman’s assay.  
Into each well of a 96-well plate was added 200 μL of each centrifuged supernatant, 100 μL of 
0.5 M pH 7 phosphate buffer - prepared by the addition of 288.55 mM Na2HPO4 (Sigma, 
MW 141.96 Da) and 211.45 mM NaH2PO4 (Sigma, MW 119.98 Da) -  and 7 μL of 2 mg/mL 
Ellman’s reagent (5,5'-dithio-bis-(2-nitrobenzoic acid) - DTNB) (Sigma, MW 396.35 Da) 
prepared in 0.5 M pH 7 phosphate buffer, and next incubated at RT for 15 minutes. Absorbance 
was measured at 412 nm directly from 96-well plate in the microplate photometer. Under the 
same conditions, a linear standard curve was prepared in the range of 0 - 0.5 mg/mL of PEG, 
prepared in milli-Q H2O, in which only the supernatant was replaced by 200 μL of PEG at 
different concentrations. Quantification of thiolated chains was determined after interpolation. 
Excess of PEG in solution indicated that saturation on the surface had been attained.  
In the current work, the synthesised AuNPs were functionalised with 0.035 mg/mL of PEG. 
Hydrodynamic diameter of synthesised AuNPs@PEG was characterised by DLS and their 
concentration determined by UV-Vis spectroscopy. 
5.2 AuNPs@PEG@BSA 
AuNPs@PEG were functionalised with Bovine Serum Albumin (BSA) (Sigma, MW 66,120 kDa) 
by a process based on a EDC/NHS reaction.  
In order to obtain a complete saturation of BSA on AuNPs@PEG, a range of concentrations of 
BSA were tested with a fixed AuNPs@PEG concentration. For that, it was first prepared a 
master mix of 21 nM synthesised AuNPs@PEG, 1.25 mg/mL sulfo-NHS (Sigma, 
MW 217.13 Da) and 0.312 mg/mL EDC (Sigma, MW 191.70 Da) in 10 mM pH 6 MES buffer (2-
(N-morpholino)ethanesulfonic acid) (Sigma, MW 195.24 Da). The master mix was incubated for 
30 minutes and then the solution was centrifuged at 14000 rpm for 30 minutes at 4 ºC. The 
supernatant was removed and replaced by 2.5 mM pH 6 MES buffer, filling up to the original 
volume. The master mix was divided into equal volumes, and 0.2 mg/ml of BSA prepared in 
milli-Q H2O was added to attain the required range of concentrations (0 - 100 μg/mL). All 
solutions were incubated for 16 hours while stirring in a shaker, at RT. 
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Afterwards 16 hours incubation, solutions were centrifuged for three times at 14000 rpm for 
30 minutes at 4 ºC to remove the excess BSA. Supernatants were removed to new eppendorfs 
and replaced by 2.5 mM pH 6 MES buffer after each centrifugation. Supernatants were also 
centrifuged at the same previous described conditions. Excess of BSA was quantified in the 
centrifuged supernatants by the Bradford assay. For that, to each well of a 96-well plate was 
added 150 μL of each centrifuged supernatant and 150 μL of Coomassie Brilliant Blue 
(Coomasie Protein Assay Kit, Thermo Scientific). After 15 minutes of incubation at RT, 
absorbance was measured at 450 and 595 nm directly from 96-well plate in the microplate 
photometer. Under the same conditions, a linear standard curve was prepared in the range of 
0 – 100 μg/mL of BSA in milli-Q H2O. In this case, 150 μL of BSA solutions at different 
concentrations and 150 μL of Coomassie Brilliant Blue were added to each well. Protein 
quantification in the supernatants was possible after interpolation in this standard curve. When 
BSA was detected in solution, it was known that the correspondent initial BSA concentration 
was sufficient to obtain the complete saturation of the protein on AuNPs@PEG. The ratio of the 
absorbance at 595 and 450 nm was utilised to obtain the linearisation of the standard curve, 
and thus Lambert-Beer law can be applied (Ernst & Zor 2010). 
In the current work, the AuNPs@PEG were functionalised with 10 µg/mL of BSA. 
Hydrodynamic diameter of synthesised AuNPs@PEG@BSA was characterised by DLS and 
their concentration determined by UV-Vis spectroscopy. 
5.3 AuNPs@PEG@HSA 
AuNPs@PEG were functionalised with Human Serum Albumin (HSA) (Sigma, MW 66,248 kDa) 
under the same conditions described in section II.5.2, in which BSA was replaced by HSA, and 
the protein concentration for the functionalisation of AuNPs@PEG was 30 µg/mL of HSA. 
6. INCUBATION OF FUNCTIONALISED AuNPs WITH TS262 AND TS265  
Solutions of 6 nM AuNPs@PEG@BSA and 6 nM AuNPs@PEG@HSA were mixed separately 
with 50 μM of TS265 or TS262 and incubated for 1 hour at 4ºC. After this period of time, 
solutions were centrifuged thrice at 14000 rpm for 30 minutes at 4 ºC, to remove excess of 
TS265 or TS262. Supernatants were replaced by autoclaved milli-Q H2O.  
All solutions were prepared in autoclaved milli-Q H2O. 
Quantification of TS265 or TS262 molecules linked to nanoparticles was performed by ICP-MS 
(Inductively Coupled Plasma Mass Spectrometry). 
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7. UV-VIS SPECTROSCOPY 
Nanoparticle solutions were characterised using an UV-Vis spectrophotometer (UVmini-1240, 
Shimadzu, Germany). The absorbance measurements were made using 100 μL of volume 
quartz absorption cells (105.202-QS, Hellma, Germany). Spectra were normalised by shifting 
the baseline to zero. 
8. TEM ANALYSIS 
TEM was performed at Instituto de Ciência e Engenharia de Materiais e Superfícies at Instituto 
Superior Técnico (ICEMS/IST), Portugal – contracted service. 
The samples were prepared by depositing 10 µL of the colloidal solution of gold in carbon 
copper grids, washing twice with milli-Q water, and air dried.  
9. DLS ANALYSIS 
The hydrodynamic diameter of nanoparticles was determined by DLS using a Nanoparticle 
Analyzer SZ-100 (Horiba Scientific, Japan) at 25 ºC, with a scattering angle of 90 º. Samples of 
2 nM of AuNPs, AuNPs@PEG, AuNPs@PEG@BSA, AuNPs@PEG@HSA, 
AuNPs@PEG@BSA-TS262, AuNPs@PEG@BSA-TS265, AuNPs@PEG@HSA-TS262 or 
AuNPs@PEG@HSA-TS265 in milli-Q H2O were prepared. A total of 10 measures were taken 
for each sample. 
10. ICP-MS ANALYSIS 
Quantification of metals was assessed by ICP-MS, performed at Laboratório de Análises – 
Serviço de Espectroscopia de Emissão Atómica at Departamento de Química (DQ) at FCT-UNL 
– contracted service. 
Samples were prepared by 200 μL aliquots of each solution, diluted in 1 mL of fresh aqua regia. 
All samples were measured in triplicate. 
11. IN VITRO CYTOTOXICITY ASSAYS OF FUNCTIONALISED AuNPs 
In a 96-well plate were seeded 7500 cells/well and incubated at 37 ºC in a 99 % humidified 
atmosphere of 5 % (v/v) CO2 for 24 hours. After this time, cells seeded were observed using an 
inverted microscope and their adherence were confirmed. CCR was removed from each well 
and replaced by (i) 100 μL of fresh culture medium, the negative control (ii) 100 μL of 
AuNPs@PEG@BSA, (iii) 100 μL of AuNPs@PEG@BSA-TS262 and (iv) 100 μL of 
AuNPs@PEG@BSA-TS265. All solutions were prepared in fresh culture medium and plating in 
triplicate. The concentrations used in this assay correspond to relative IC50 of free TS262 and 
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TS265 complexes in human cell lines, determined through in vitro cytotoxicity assay (see 
section II.3.4).  
Under the same conditions, in vitro cytotoxicity assay was performed for AuNPs@PEG@HSA, 
AuNPs@PEG@HSA-TS262 and AuNPs@PEG@HSA-TS265. 
After that, cells were incubated for 48 hours at 37 ºC in a 99 % humidified atmosphere of 
5 % (v/v) CO2. Subsequent to 48 hours incubation, cell viability was determined following the 
described protocol in section II.3.3. 
12. STEADY-STATE FLUORESCENCE SPECTROSCOPY 
Studies of the interaction between serum albumin and TS262 and TS265 were performed by 
steady-state fluorescence spectroscopy. The fluorescence intensity measurements were 
performed at RT using a Cary Eclipse Fluorescence spectrophotometer at excitation 
wavelength of 295 nm and recorded in the frequency range of 300 – 500 nm. BSA and HSA 
concentrations were kept constant (2.0 µM), and incubated with different concentrations of 
TS262 and TS265 (Table II.2):  
Table II.2 – Range of concentrations of the metallic compounds TS262 and TS265 used for the incubation 
with BSA and HSA, to perform the fluorescence assays. 
 TS262 (µM) TS265 (µM) 
BSA (2.0 µM) 0 – 400 0 - 375 
HSA (2.0 µM) 0 - 90 0 - 130 
 
BSA and HSA stock solutions were prepared in 10 mM pH 7.0 phosphate buffer with 0.15 M 
NaCl while TS262 and TS265 stock solutions were prepared in milli-Q H2O. The samples of 
serum albumin and of each compound were mixed in order to obtain the desired concentrations 
and next incubated for 1 hour at 4 ºC, the same incubation time and temperature used in 
section II.6, before being analysed by fluorescence spectroscopy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
III. RESULTS AND DISCUSSION 
1. CYTOTOXIC POTENTIAL OF TS262 AND TS265 
The in vitro studies in tumour cell lines are the initial step for the identification of new potential 
anticancer compounds. Only the compounds which are capable of significantly reduce tumour 
cell viability are selected as promising in cancer treatment. 
TS262 and TS265 compounds were previously tested in a range of concentrations of 
0.1 - 100 µM in HCT116 cell line (human colorectal carcinoma cell line), and there was a 
pronounced decrease in cell viability dependent on the increase of those concentrations (Luís 
2011). Their previously reported anti-proliferative potential, prompted us, to continue the study 
of both compounds in HCT116 cell line. Two other tumour cell lines were also used for 
cytotoxicity studies of these compounds: A549 and H1975 cell lines, human lung carcinoma and 
human lung adenocarcinoma cells, respectively. Lung and colorectal cancers are the third and 
fourth most common cancer types in the world, respectively (GLOBOCAN, 2012). 
The stock solutions of TS262 and TS265 were initially characterised by ICP-MS in order to 
quantify the zinc and cobalt atoms in both solutions, respectively. ICP-MS is one of the most 
utilised analytical techniques for the detection and quantification of small quantities of metals in 
solution (Stephan & Hineman 2012). From the results obtained it was concluded that the 
amount of zinc detected in TS262 samples was 2.14 ± 0.53 % higher and the amount of cobalt 
atoms in TS265 samples was 29.7 ± 0.45 % smaller than would be expected. According to 
these results, all compound concentrations were corrected in all assays shown below. 
The evaluation of cytotoxicity of TS262 and TS265 in A549 and H1975 cell lines was performed 
by MTS assay. MTS is reduced into a formazan product, soluble in cell culture medium, by 
dehydrogenase enzymes found in metabolically active cells. Thus, the amount of formazan 
product, measured at 490 nm, is a measure of the metabolic viability of the cells which directly 
correlates with cell viability. The anticancer potential of TS262 and TS265 was tested on a 
range of increasing concentrations on both tumour cell lines, in which cells were exposed to 
compounds for 48 hours. The percentage of cell viability obtained for A549 and H1975 cell lines 
are represented in Figure III.1 and Figure III.2, respectively. 
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Figure III.1 – Cell viability in A549 human cell line obtained by MTS assay after exposure to (A) TS262 
(0.1 – 41 μM) and (B) TS265 (0.1 – 28 μM) for 48 hours. Percentage of cell viability for each concentration 
is relative to the mean of three independent assays and error bars are correspondent to Standard Error of 
the Mean (SEM). 
 
 
Figure III.2 – Cell viability in H1975 human cell line obtained by MTS assay after exposure to (A) TS262 
(0.1 – 41 μM) and (B) TS265 (0.1 – 28 μM) for 48 hours. Percentage of cell viability for each concentration 
is relative to the mean of three independent assays and error bars are correspondent to SEM. 
There was a decrease in cell viability in both A549 and H1975 cell lines, dependent on the 
increase of TS262 and TS265 concentrations, showing the great potential of these compounds 
as anti-proliferative agents. Based on these results it was determined the relative IC50 values, 
that correspond to the required concentration of each compound to reduce cell viability in 50 %, 
compared to the control, i.e. untreated cells. For A549 cell line, the relative IC50 values 
determined was 0.714 ± 0.091 µM for TS262 and 0.741 ± 0.007 µM for TS265. In the case of 
H1975 cell line, the relative IC50 values are also similar for both compounds: 0.355 ± 0.038 µM 
for TS262 and 0.349 ± 0.021 µM for TS265. Despite the similar IC50 values, both compounds 
show higher in vitro anti-proliferative activities for H1975 cancer cell line. 
Previously, our laboratory has reported IC50 values in HCT116 cell line of 0.217 ± 0.022 µM for 
TS262 and 0.206 ± 0.023 µM for TS265, under the same conditions (Silva et al. 2013b). The in 
vitro anti-proliferative activities of TS262 and TS265 were also tested in healthy human 
fibroblasts, demonstrating a higher (3.5x) anti-proliferative activity towards HCT116 cancer cells 
compared to fibroblasts (IC50 values determined in 0.62 µM and 0.60 µM for TS262 and TS265, 
respectively) (Luís et al. 2014). This increased selectivity for normal cells was also observed 
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when compared their activity in H1975 cancer cells with the activity in healthy fibroblasts cells. 
However, the same behaviour was not observed when compared with A549 cancer cells. The 
TS265 was also tested in MCF-10A, a normal human epithelial cell line from mammary gland, 
and your relative IC50 value was determined in 5.14 ± 0.01 µM (Luís et al. 2014). This value is 
much higher than all relative IC50 values determined for TS265 in the three epithelia type cancer 
cell lines: HCT116, A549 and H1975. These results clearly show that both compounds are 
much more cytotoxic to the three cancer cells when compared to normal epithelial cells. 
Nevertheless, their IC50 values in normal fibroblasts indicate that for reducing cellular toxicity in 
vivo, they should be targeted towards cancer cells. The viability assay in MCF-10A cell line 
should be also performed for TS262 compound. 
2. SYNTHESIS AND CHARACTERISATION OF AuNPs 
AuNPs have been proposed for cancer treatment based on their great advantages as a vehicle 
for drug delivery. In particular, AuNPs due to their straightforward synthesis with size and shape 
control, accessible methods for their characterisation, easily surface functionalisation and the 
ability to penetrate into tumour cells in in vitro assays have been widely used (Silva et al. 
2014c).  
AuNPs were successfully synthesised by the reduction of HAuCl4 solution with sodium citrate, 
characterised by UV-Vis spectroscopy, TEM and DLS, and used throughout this study. UV-Vis 
spectroscopy is the most common used method for characterise the optical properties of AuNPs 
due to the SPR band of colloidal gold (Shi et al. 2012). This SPR band is strongly dependent on 
the size, shape, dispersity and local environment of the nanoparticles (Abdelhalim et al. 2011, 
Shi et al. 2012). Figure III.3A shows the UV-Vis absorption spectra of the synthesised AuNPs at 
a pH 7.0 solution. A symmetric absorption peak, indicative of monodisperse and spherical 
nanoparticles (Shi et al. 2012), is observed at 519 nm, typical of this type of AuNPs, i.e. with an 
approximate diameter of 14 nm (Lien Nghiem et al. 2012). The colloidal gold concentration 
could be also calculated based on this absorption spectrum by the Lambert-Beer law, assuming 
a molar absorptivity for the plasmon resonance band maximum of 2.33 × 10
8
 M
-1
cm
-1
 (Baptista 
et al. 2005, Conde et al. 2012b). The expected usual concentration in this type of synthesis 
should be ~14 nM of AuNPs (Conde et al. 2012b). 
TEM has been also found to be a powerful tool for the characterisation of AuNPs, providing 
direct visualisation of the morphology and size distribution of nanoparticles (Murawska et al. 
2012). The TEM results (Figure III.3B) confirmed the great monodispersion of AuNPs and their 
spherical shape. The average particle size was also determined from TEM images with a mean 
diameter of 14.26 ± 0.31 nm. These results were in agreement with the UV-Vis results.  
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Figure III.3 – Characterisation of the synthesised AuNPs with the mean diameter of about 14 nm by 
(A) UV-Vis spectroscopy in the wavelength range of 400 - 800 nm (pH 7.0), and (B) TEM (scale bar: 20 
nm). 
 
Characterisation through DLS can also give powerful and complementary information about 
AuNPs. In this technique, small particles in suspension undergo random thermal motion known 
as Brownian motion, which is directly related to the AuNPs hydrodynamic diameter. The 
determination of nanoparticles hydrodynamic diameter was computed from the intensity of the 
scattered light and processed by the instrument software, based on the theory of Brownian 
motion and Stokes-Einstein equation (Equation III.1) (Dynamic Light Scattering, HORIBA 
Scientific, 2014):  
(III.1) 
 
, where Dh is the hydrodynamic diameter, kB the Boltzmann’s constant, T the thermodynamic 
temperature, Dt is the translational diffusion coefficient and ƞ is the dynamic viscosity. The DLS 
results revealed an AuNPs average hydrodynamic diameter of 14.14 ± 0.43 nm. This method 
also confirmed the expected size of nanoparticles.   
3. CHARACTERISATION OF FUNCTIONALISED AuNPs 
 3.1 AuNPs@PEG 
The prepared AuNPs were then coated with PEG molecules to increase their stability and 
biocompatibility, and also provide the chemical functionality of further derivatisation. Figure III.4 
(red line) shows the UV-Vis absorption spectrum of the stabilised AuNPs@PEG. The plasmon 
absorption peak of naked AuNPs (see black line, Figure III.4) clearly shifts from 519 to 522 nm 
after their functionalisation with PEG. This shift means that there was a change in the nature 
surrounding the AuNPs, confirming the Au-S covalent bond between nanoparticles and PEG. 
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Figure III.4 – Spectra of the previous synthesised AuNPs and AuNPs@PEG obtained by UV-Vis 
spectroscopy, in the wavelength range of 400 - 800 nm (pH 7.0).  
Figure III.4 shows a constant absorption spectrum of AuNPs@PEG meaning that the amount of 
PEG utilised (0.035 mg/ml) to cover the entire surface of AuNPs was capable to maintained 
these nanosystem stable in a pH 7 solution (milli-Q H2O). The amount of thiolated chains 
covalently bounded to each AuNP was determined by Ellman’s method (Figure VI.1, 
appendices). A AuNP:PEG ratio of 1:5591 (± 157) was obtained. These results were in 
agreement with previous studies, in which AuNPs with a hydrodynamic diameter of 14.47 nm 
were covered with a dense layer of PEG (MW = 458.57 Da), wherein a AuNP:PEG ratio of 
1:5624 was calculated (Conde et al. 2012a).  
The AuNPs modified surface was also characterised through DLS with an average 
hydrodynamic diameter determined on 35.20 ± 1.26 nm. There was clearly an increase on 
particle size of about 20 nm when the citrate ions were replaced by PEG molecules. It is thought 
that there was a triple layer of PEG capping AuNPs since each PEG molecule size is 3.25 nm 
(http://www.iris-biotech.de/). Theoretically, if a monolayer of PEG covering the AuNPs was 
present, the hydrodynamic diameter of these modified nanoparticles would be about 20 nm 
(assuming a linear molecule, i.e. “stretched”). However, the hydrodynamic diameter of 
AuNPs@PEG may be misrepresented. PEG is very flexible and may influence the Brownian 
motion of the particles by reducing the AuNPs dynamic viscosity and thus increasing their 
hydrodynamic diameter (Rahme et al. 2013). 
3.2 AuNPs@PEG FUNCTIONALISED WITH SERUM ALBUMIN AND THE 
METALLIC COMPOUNDS 
Serum albumin is the most abundant protein in blood plasma (Housni et al. 2008). This protein 
provides the intracellular binding, transportation and delivery of endogenous and exogenous 
compounds (Sankareswari et al. 2014, Trnková et al. 2010), such as fatty acids, steroids, metal 
ions, metabolites and a large number of pharmaceutical agents (Sankareswari et al. 2014). It is 
well known this ability of serum albumin to bind non-covalently with small molecules (Housni et 
al. 2008), resulting in an increased solubility of ligands in plasma and enhanced delivery to the 
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target sites (Can et al. 2012). Therefore, BSA and HSA have a great importance in 
nanomedicine due to their biocompatible, and also due to their water solubility. Their 
functionalisation with different functional groups on their surface also makes them an interesting 
targeted-based drug delivery system (Housni et al. 2008). 
BSA is a globular protein composed of 583 amino acid residues. It contains three homologous 
domains (I – III), where each one comprises two sub-domains (A and B) paired by 17 disulfide 
bonds (Tayeh et al. 2009, Xu et al. 2013).The BSA binding sites for endogenous and 
exogenous molecules may be situated in sub-domains IIA and IIIA (Sudlow’s sites I and II, 
respectively) (Xu et al. 2013). In the current work, the BSA was covalently bound to the 
synthesised AuNPs@PEG by using the EDC/sulfo-NHS reaction. The resulting 
AuNPs@PEG@BSA were then characterised by UV-Vis spectroscopy and DLS, and the 
number of BSA molecules per AuNP was estimated by the quantification of supernatants using 
the Bradford assay. The UV-Vis spectrum of AuNPs@PEG@BSA clearly shows a shift from 
522 to 525 nm (see black line in Figure III.5), which is attributed to changes in the nature 
surrounding AuNPs@PEG due to BSA binding. The protein binding to PEG molecules was also 
confirmed through the DLS technique, where there was an increase in hydrodynamic diameter 
of the functionalised particles from 35.20 nm to 42.03 ± 0.75 nm. A final AuNP:BSA ratio of 1:5 
(±1) was obtained by the Bradford assay (Figure VI.2, appendices). Considering a 
hydrodynamic diameter of 7 nm (Yohannes et al. 2010), and assuming a spherical conformation 
for the protein, the superficial area of each BSA is 153.86 nm
2
. However, take into consideration 
the superficial area of an AuNP@PEG and the AuNP:BSA ratio, each BSA molecule was 
occupying 772.91 nm
2
 in the particle. The coupling of proteins to the activated carboxyl groups 
carried out usually via lysines residues (Fischer 2010). Each BSA molecule has 60 lysines 
residues able to bind the activated carboxyl groups of PEG molecules (www.uniprot.org), which 
can lead to conformational changes of the protein, thus justifying the occupation of a larger area 
on the AuNP@PEG surface. 
HSA shows 80 % similarity to BSA in primary structure (Sankareswari et al. 2014). HSA is 
composed of 585 amino acid residues, containing also 17 disulfide bonds and one free 
cysteine. Similar to the tertiary structure of BSA, HSA contains three homologous domains 
(I - III) which are divided into two sub-domains (A and B) (Can et al. 2012). AuNPs@PEG were 
also successfully functionalised with HSA. The UV-Vis spectrum shows a shift from 522 to 
526 nm, confirming the protein binding to PEG molecules on the AuNP surface (see black line, 
Figure III.6). The increase in hydrodynamic diameter of HSA from 35 to 40.66 ± 0.70 nm, 
obtained by DLS technique, was consistent with the UV-Vis results. Bradford assay 
(Figure VI.3, appendices) corroborated that the amount of HSA coupled to AuNP@PEG was 
twice the amount of BSA, with the ratio 1:11 (±1) of AuNP:HSA . Despite being very similar 
proteins, HSA occupied a smaller area (353.05 nm
2
/HSA) of the functionalised nanoparticle 
than BSA. Small changes in the amino acid sequences can have tremendous effects on protein 
structure. Many of the albumin differences are at residues that are surface-exposed and this is 
 
33 
 
reflected in terms of hydrophilicity/hydrophobicity of the HSA and BSA (Akdogan et al. 2012). 
The water molecules lead to their different conformational adaptability and flexibility, and BSA 
showed to be less flexible in a water solution than HSA, and in turn, HSA showed to be more 
hydrophobic than BSA (Akdogan et al. 2012). This reported study could explain the fact of 
having more HSA molecules on the surface of the functionalised particles than BSA molecules. 
After protein functionalisation, AuNPs@PEG@BSA and AuNPs@PEG@HSA were incubated 
with TS262 and TS265 and characterised by UV-Vis spectroscopy, DLS and ICP-MS. A shift for 
longer wavelengths was observed when the metallic compounds binds to AuNPs@PEG@BSA 
than AuNPs@PEG@HSA. The bonding is corroborated by the DLS and ICP-MS results, 
showing, respectively, an increase in hydrodynamic diameters of the particles and higher 
compound:albumin ratios in almost all red-shifted samples. 
The UV-Vis spectrum of AuNPs@PEG@BSA-TS262 shows a clearly shift from 525 to 533 nm 
(see red line, Figure III.5) and DLS showed a large increase in hydrodynamic diameter from 
42.03 to 83.01 ± 1.43 nm. In turn, the UV-Vis spectrum of AuNPs@PEG@BSA-TS265 shows a 
shift from 525 to 535 nm (see blue line, Figure III.5) and DLS a large increase in hydrodynamic 
diameter from 42.03 to 88.60 ± 5.80 nm. The amount of TS262 and TS265 molecules per 
AuNP@PEG@BSA, after digestion with aqua regia, was determined by ICP-MS technique to be 
764 ± 120 and 612 ± 23 molecules, respectively. According to the results obtained by UV-Vis 
and DLS, it was expected that the amount of TS265 molecules per AuNP@PEG@BSA was 
higher than TS262 molecules. Nevertheless, AuNPs@PEG@BSA can have a greater number 
of TS265 on their surface, since the SEM associated to the number of TS262 molecules was 
quite large, and the result could be unreliable. Several samples with different concentrations of 
functionalised particles and compounds were analysed by ICP-MS, and with different incubation 
times (data not shown). The higher ratios of compound:AuNP were observed in all the 
conditions used in this work.  
 
 
Figure III.5 – Spectra corresponding to the AuNPs@PEG@BSA, AuNPs@PEG@BSA-TS262, 
AuNPs@PEG@BSA-TS265, obtained by UV-Vis spectroscopy in the wavelength range of 400 - 800 nm 
(pH 7.0). 
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Regarding the AuNPs@PEG@HSA-TS262, the UV-Vis spectrum shows a shift from 526 to 
529 nm (see red line, Figure III.6) and an increase in hydrodynamic diameter from 40.66 to 
76.21 ± 1.55 nm was observed by DLS. Regarding the AuNPs@PEG@HSA-TS265, the UV-Vis 
spectrum also shows a shift for higher wavelengths from 526 to 532 nm (see blue line, 
Figure III.6), and the DLS results are in agreement with these obtained data, confirming the 
successful link of the compound to the functionalised nanoparticles, with an increase in 
hydrodynamic diameter from 40.66 to 84.67 ± 1.68 nm. The amount of TS262 and TS265 
molecules per AuNPs@PEG@HSA was also determined by ICP-MS in 307 ± 23 and 432 ± 8 
molecules, respectively.  
 
Figure III.6 – Spectra corresponding to the AuNPs@PEG@HSA, AuNPs@PEG@HSA-TS262, 
AuNPs@PEG@HSA-TS265, obtained by UV-Vis spectroscopy in the wavelength range of 400 - 800 nm 
(pH 7.0). 
According to these results, the ability of BSA to bind the metallic compounds was higher than 
that of HSA. Despite the lower amount of BSA on the particle compared to the amount of HSA 
(5 vs. 11 proteins per AuNP, respectively) there was an increase in the final concentrations of 
both compounds bound to BSA. For both cases this shows that a significant number of 
molecules may carried on these developed AuNPs drug delivery vehicles.  
Presence of the compounds on the AuNPs’ surface was also demonstrated via the alterations of 
the maximum absorbance wavelengths of TS262 and TS265 (254 nm and 253 nm for TS262 
and TS265, respectively) (Figure VI.4, appendices) The UV-Vis spectra corresponding to the 
functionalised AuNPs clearly show the presence of both compounds surrounding 
AuNPs@PEG@BSA and AuNPs@PEG@HSA (Figure VI.5 and Figure VI.6, appendices). The 
molar extinction coefficients was determined: 55300 M
-1
 cm
-1 
and 34900 M
-1
 cm
-1
 for TS262 and 
TS265, respectively (Figure VI.7 and Figure VI.8, appendices). 
Although many studies based on serum albumin-AuNPs nanosystems have been described, 
most of them are performed with BSA and only a small number are reported with the albumin 
from the human serum. The current work provides the advantage of develop a HSA-AuNP 
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bioconjugate for drug delivery and also the opportunity of compare it with the homologous 
BSA-AuNP nanosystem.  
4. CYTOTOXICITY ASSAYS OF FUNCTIONALISED AuNPs 
After obtaining the functionalised and characterised AuNPs, in vitro cytotoxicity assays in 
HCT116, A549 and H1975 cell lines were performed. For that, cell viability assays for 
functionalised AuNPs (taking into consideration the compounds at their relative IC50) were 
made. We intended to verify if the functionalised AuNPs carrying the compounds could bring 
advantages compared to the use of free TS262 and TS265 in cancer treatment (e.g. dose 
reduction, reduced toxicity in healthy cells, etc). 
The cells were exposed to the functionalised AuNPs for 48 hours and the evaluation of the 
induced cytotoxicity was performed by MTS assay. Figure III.7 shows the percentage of cell 
viability obtained for the A549 cell line. AuNPs@PEG@BSA and AuNPs@PEG@HSA 
decreased the cell viability of about 30 % and 40 %, respectively. In turn, those functionalised 
AuNPs carrying the TS265 reduced the cell viability in approximately 80 %. It should be noted 
that this decrease of cell viability was attained at the concentration of free TS265 that induced 
50 % of cell death. Thus, the combined treatment resulted in a greater inhibition of cell activity 
than single treatment with TS265. The results suggested that there was an additive effect of 
AuNPs@PEG@BSA or AuNPs@PEG@HSA and TS265 since there was a significant negative 
effect in cell viability resulting from both systems. Hence, the developed AuNP-based 
nanosystems demonstrated to be efficient drug delivery systems for TS265 in A549 tumour cell 
line.  
 
Figure III.7 – Cell viability in A549 human cell line obtained by MTS assay after exposure to functionalised 
AuNPs for 48 hours. In this assays was used the concentration of the functionalised AuNPs that contains 
the amount of TS265 corresponding to its previous determined relative IC50 (see section III.1). The 
percentage of cell viability for each formulation is relative to the mean of two independent assays and error 
bars are correspondent to SEM.   
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In A549 cancer cell line and under the same incubation conditions (i.e. volume of solution used, 
dilution of the functionalised AuNPs in culture medium, etc) it was not possible to reach the 
corresponding relative IC50 of TS262 on AuNPs@PEG@HSA surface. Thus, for this cell line 
only the AuNPs nanoconjugates containing the TS265 compound were used.  
The AuNPs@PEG@BSA and AuNPs@PEG@HSA triggered a slight decrease (approximately 
5 % and 10 %, respectively) in the viability of H1975 cancer cells (Figure III.8). This shows the 
nanoconjugates’ low toxicity in this type of cancer cells. The AuNPs carrying the TS262 
(Figure III.8A) demonstrated to have a less pronounced anti-proliferative potential than the 
AuNPs containing TS265 on their surface (Figure III.8B).  
  
Figure III.8 – Cell viability in H1975 human cell line obtained by MTS assay after exposure to 
functionalised AuNPs for 48 hours: (A) functionalised AuNPs with and without TS262 and 
(B) functionalised AuNPs with and without TS265. In this assays was used the concentration of the 
functionalised AuNPs that contains the amount of TS262 or TS265 corresponding to its previous 
determined relative IC50 (see section III.1). The percentage of cell viability for each formulation is relative to 
one assay. 
The reduction on cell viability obtained for AuNPs@PEG@BSA-TS262 and 
AuNPs@PEG@HSA-TS262 was about 50 % and 40 %, respectively, indicating the similarity 
with the use of the TS262 alone to induce cell death in H1975 cancer cells. Thus, in regard to a 
possible reduction of the required dose of this anticancer agent, there was no advantage of 
using those nanoparticle systems in this type of lung cancer.  
Both AuNPs@PEG@BSA-TS265 and AuNPs@PEG@HSA-TS265 demonstrated to be 
promising targeted-based drug delivery systems. There was a pronounced decrease in H1975 
cell viability of about 70 % in both cases, at the TS265 concentration that induced 50 % of cell 
death when the compound was used in the free form. These results suggested that there was a 
synergistic effect of AuNPs@PEG@BSA or AuNPs@PEG@HSA and TS265 since the TS265 
anticancer effect was enhanced when combined with the functionalised AuNPs.  
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Absence of cytotoxicity from AuNPs@PEG@BSA and AuNPs@PEG@HSA in HCT116 cell line 
is shown in Figure III.9.  
  
 Figure III.9 – Cell viability in HCT116 human cell line obtained by MTS assay after exposure to 
functionalised AuNPs for 48 hours: (A) functionalised AuNPs with and without TS262 and 
(B) functionalised AuNPs with and without TS265. In this assays was used the concentration of the 
functionalised AuNPs that contains the amount of TS262 or TS265 corresponding to its previous 
determined relative IC50 (Silva et al. 2013b). The percentage of cell viability for each formulation is relative 
to the mean of two independent assays and error bars are correspondent to SEM.   
The HCT116 cancer cells exposed to AuNPs@PEG@BSA-TS262 and 
AuNPs@PEG@HSA-TS262 suffered a reduction in cell viability of approximately 50 % and 
60 %, respectively. The AuNPs@PEG@BSA-TS262 system showed an equivalent 
anti-proliferative potential to that of TS262 alone. Hence, for H1975 cancer cells, the proposed 
nanoconjugate brings no benefit in terms of reducing the required dose to induce a substantial 
effect. However, exposure the HCT116 cancer cells to AuNPs@PEG@HSA and 
AuNPs@PEG@HSA-TS262 systems, suggest a synergistic effect of AuNPs@PEG@HSA and 
TS262, since the TS262 anti-proliferative potential was enhanced in 10 % when combined with 
the functionalised AuNPs. 
It was also observed that either AuNPs@PEG@BSA-TS265 or AuNPs@PEG@HSA-TS265 
had an inhibitory effect of about 60 % on HCT116 cellular activity. Thus, the treatment with a 
combination of functionalised AuNPs and TS265 decreased the cell viability in more 10 % 
compared to the use of TS265 alone. Since the functionalised particles without the compound 
on their surface showed no toxicity in HCT116 cancer cells and the effect of TS265 was 
enhanced, it also suggests that AuNPs@PEG@BSA or AuNPs@PEG@HSA work 
synergistically with TS265 to reduce the viability of HCT116 cancer cells. 
Briefly, the results suggested that AuNPs@PEG@BSA-TS265 and AuNPs@PEG@HSA-TS265 
may provide promising alternative systems for cancer treatment, being able to reduce in vitro 
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the required doses of the TS265 in A549, H1975 and HCT116 cell lines. Also the 
AuNPs@PEG@HSA-TS262 showed to be a favourable in vitro drug delivery system, reducing 
the required doses of TS262 in HCT116 cell line. Only the AuNPs@PEG@BSA-TS262 showed 
no advantage comparing to the anti-proliferative effect of the compound alone in the two tested 
cell lines.  
5. STEADY-STATE FLUORESCENCE – INTERACTION OF TS262 AND 
TS265 WITH SERUM ALBUMIN  
The tertiary structure and function of proteins are shaped by electrostatic interactions that it 
maintains with its surrounding environment. Fluorescence from the tryptophan appeared as an 
easily method for probing electrostatic interactions since this amino acid is highly sensitive to 
the polarity of the environment (Vivian & Callis 2001). Therefore, the intrinsic fluorescence of 
tryptophan is commonly used to monitor conformational changes in the proteins due to 
protein-ligand interactions (Shi et al. 2012). The maximum emission wavelength of tryptophan is 
correlated with the degree of exposure to the surrounding solvent, ranging from ~308 to 
~355 nm (Vivian & Callis 2001). Besides tryptophan, tyrosine and phenylalanine are two other 
amino acid residues that contribute to the UV fluorescence of the proteins. However, when 
protein fluorescence is excited at wavelengths equal or longer than 295 nm, the absorption is 
due mainly to tryptophan (Lakowicz 2006).  
Each BSA molecule has two tryptophan residues, Trp-134 and Trp-212, located near the 
surface of the molecule in sub-domain IB (hydrophilic environment) and in a hydrophobic pocket 
in sub-domain IIA, respectively (Trnková et al. 2010). HSA has one single tryptophan residue, 
Trp-214, contributing to its intrinsic fluorescence, and is located in a similar hydrophobic 
environment (sub-domain IIA) than Trp-212 of BSA (Kamal & Behere 2005). Taking advantage 
of the intrinsic fluorescence of BSA and HSA due to its tryptophan residues, the fluorescence 
quenching of these proteins at various concentrations of TS262 and TS265 were studied. The 
great purpose of these assays was to confirm that each BSA and HSA molecules could interact 
with the number of TS262 and TS265 molecules determined by ICP-MS. For that, was fixed a 
concentration of 2.0 µM for each serum albumin, varying the compound concentrations, in 
which was tested the compound concentration corresponding to the ratio compound:AuNP 
obtained by ICP-MS technique, and further concentrations above and below this.  
The fluorescence quenching spectra of BSA at different concentrations of TS262 is shown in 
Figure III.10. In the absence of TS262, the maximum emission wavelength was attributed only 
to the intrinsic fluorescence of BSA molecule and was observed at 350 nm (see “free BSA” in 
Figure III.10 and Figure III.11). The effect of TS262 complex on BSA molecule was very 
pronounced, in which there was a remarkable intrinsic fluorescence decrease of BSA with the 
increase of compound concentration, reaching a decrease of about 89 % at the highest TS262 
concentration used (i.e. 400 µM) – see inset in Figure III.10. 
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Figure III.10 – Steady-state fluorescence quenching spectra of BSA (fixed concentration at 2.0 µM) 
obtained through the binding of increasing concentrations of TS262 complex (0 – 400 µM), incubated for 1 
hour at 4ºC in 10 mM pH 7 phosphate buffer/0.15 M NaCl (λexc = 295 nm). The tested concentration of 
305.6 µM of TS262 was equivalent to the molar ratio of TS262:AuNP@PEG@BSA, obtained by ICP-MS. 
Inset: percentage of relative fluorescence intensity of BSA at λem = 350 nm with increasing complex 
concentration. 
The steady-state fluorescence spectra of BSA incubated with TS265 (Figure III.11) shows that 
the BSA fluorescence emission intensity decreased as well with the increase of TS265 
concentrations. In this case there was a decay of about 91 % of the intrinsic fluorescence of 
BSA at the highest TS265 concentration used (i.e. 375 µM) – see inset in Figure III.11. 
 
 
Figure III.11  – Steady-state fluorescence quenching spectra of BSA (fixed concentration at 2.0 µM) 
obtained through the binding of increasing concentrations of TS265 complex (0 – 375 µM), incubated for 1 
hour at 4ºC in 10 mM pH 7 phosphate buffer/0.15 M NaCl (λexc = 295 nm). The tested concentration of 
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244.8 µM of TS265 was equivalent to the molar ratio of TS265:AuNP@PEG@BSA, obtained by ICP-MS. 
Inset: percentage of relative fluorescence intensity of BSA at λem = 350 nm with increasing complex 
concentration. 
As the fluorescence intensity of BSA gradually decreased when the concentrations of TS262 or 
TS265 increased, it was confirmed that the compounds act as quenchers and exists the 
interaction between them and the fluorophore. It is described that the ability of albumin to 
associate non-covalently with smaller molecules and ions is due to the existence of at least six 
binding regions in the protein, two high affinity binding sites, situated in Sudlow’s sites I and II 
as previously described, and a number of sites with lower affinity for ligands (Shahabadi et al. 
2012). In these fluorescence studies, the BSA was in its native conformation, in the absence of 
the compounds, contrary to the BSA molecules covalently linked to PEG on the AuNPs surface. 
The as-prepared AuNPs@PEG@BSA was incubated with a high concentration of compounds 
(50 µM), and was verified by ICP-MS technique that the maximum of molecules that the protein 
could bind was about 153 and 122 molecules of TS262 and TS265, respectively (764 ± 120 and 
612 ± 23 molecules of TS262 and TS265 per AuNP, respectively, as previously described in 
section III.3.2). When were tested higher molar ratios of compound:BSA than these, and 
analysed by steady-state fluorescence, it was confirmed that each BSA molecule could interact 
with a great number of TS262 and TS265 molecules since there was still a decay in 
fluorescence, which was an evidence for continuous conformational changes of BSA. The fact 
of BSA be covalently bound to PEG in AuNPs@PEG@BSA may lead to the steric hindrance of 
the molecule due to its altered tertiary structure, and also lead to the occupation of several 
binding sites, interacting with less molecules than in its free conformation. The fact that they are 
only described two high affinity sites for the binding of ligands to BSA, suggests that almost all 
TS262 and TS265 molecules were bound to a large number of weaker binding sites. The 
interactions of TS262 and TS265 with these lower affinity sites for ligands could be also 
supported by the fact of the quenching of the tryptophan residues fluorescence was very strong 
at lower molar ratios, but in higher molar ratios it progressed weakly, suggesting weaker binding 
sites for the compounds, and probably located away from the fluorophore. The nature of the 
interaction between almost all compound molecules and BSA could be electrostatic since the 
isoelectric point of BSA is 4.7 (Chaudhary et al. 2014) and the experimental pH ~7, i.e. BSA 
possesses a negative charge whereas the compounds are positive charged.   
Incubated at the same conditions, the maximum emission wavelength of free HSA (i.e. in the 
absence of TS262 or TS265) was observed at 344 nm (see “free HSA” in Figure III.12 and 
Figure III.13) instead of a maximum wavelength of 350 nm, attributed to the fluorescence 
intensity of free BSA. The difference between the maximum emission wavelengths of free BSA 
and free HSA can be related with the presence of Trp-134 in BSA, which is located in a more 
hydrophilic environment than the Trp-212 or the Trp-214 in HSA, influencing the maximum 
emission for longer wavelengths by being more exposed to the solvent (Varlan & Hillebrand 
2010). Furthermore, the maximum intensity of the fluorescence emission of BSA was 
 
41 
 
approximately twice than the maximum intensity of HSA in the absence of the compounds, 
suggesting that the Trp-134 has similar fluorescence intensity than Trp-212 and Trp-214. 
The gradual decay of the intrinsic fluorescence of HSA was also observed as the concentration 
of TS262 increased (Figure III.12). There was an effect of the TS262 complex on HSA molecule 
which leads to a decrease in fluorescence of about 65 % at the higher molar ratio tested 
(i.e. 90 µM) – see inset in Figure III.12.  
 
Figure III.12  – Steady-state fluorescence quenching spectra of HSA (fixed concentration at 2.0 µM) 
obtained through the binding of increasing concentrations of TS262 complex (0 – 90 µM), incubated for 1 
hour at 4ºC in 10 mM pH 7 phosphate buffer/0.15 M NaCl (λexc = 295 nm). The tested concentration of 
55.8 µM of TS262 was equivalent to the molar ratio of TS262:AuNP@PEG@HSA, obtained by ICP-MS. 
Inset: percentage of relative fluorescence intensity of HSA at λem = 344 nm with increasing complex 
concentration. 
The steady-state fluorescence spectra of HSA incubated at different concentrations of TS265 
also shows a reduction in fluorescence emission intensity with the increasing of the compound 
concentration (Figure III.13). In this case there was a decay of about 82 % of the intrinsic 
fluorescence of free HSA at the highest TS265 concentration tested (i.e. 130 µM) – see inset in 
Figure III.13. The data corresponding to the incubation of the protein with a final concentration 
of 10 µM of TS265 does not make sense. The fluorescence intensity was not in agreement with 
the results obtained at higher molar ratios of TS265:HSA (i.e. equal or higher than 30 µM of 
TS265) - see inset in Figure III.13. An error may have occurred while preparing the solution and 
the data should be excluded. 
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Figure III.13 – Steady-state fluorescence quenching spectra of HSA (fixed concentration at 2.0 µM) 
obtained through the binding of increasing concentrations of TS265 complex (0 – 130 µM), incubated for 1 
hour at 4ºC in 10 mM pH 7 phosphate buffer/0.15 M NaCl (λexc = 295 nm). The tested concentration of 
78.5 µM of TS265 was equivalent to the molar ratio of TS265:AuNP@PEG@HSA, obtained by ICP-MS. 
Inset: percentage of relative fluorescence intensity of HSA at λem = 344 nm with increasing complex 
concentration. 
The results obtained by the steady-state fluorescence assays for the binding of HSA to TS262 
or TS265 molecules also confirmed the interaction between the protein and both compounds. 
Several binding sites have been reported for HSA. Nevertheless it is accepted the dominance of 
two high affinity sites for the binding of ligands, situated at Sudlow’s sites I and II (Can et al. 
2012), such as in the homologous BSA. As well as BSA, it was confirmed in these assays that 
the HSA could interact with a large number of TS262 or TS265 molecules when the protein was 
in its native conformation compared to HSA covalently bounded to PEG in 
AuNPs@PEG@HSA. The AuNPs@PEG@HSA was also incubated with a high concentration of 
compounds (50 µM), and was verified by ICP-MS technique that the maximum of molecules that 
the protein could bind was about 28 and 39 molecules of TS262 and TS265, respectively 
(307 ± 23 and 432 ± 8 molecules of TS262 and TS265 per AuNP, respectively, as previously 
described in section III.3.2). Higher molar ratios of compound:HSA still show a decay in 
fluorescence emission, being an evidence of continuous interactions between TS262 or TS265 
and the possible binding sites of HSA. In fact, the existence of one binding site for TS265 at a 
distance of ~1.5 nm from Trp-214 has been reported, not excluding other binding sites for the 
ligand (Luís et al. 2014). This study also reported the existence of a reversible interaction of the 
compound with the HSA, indicating its promising potential to be delivery in tumour cells, taking 
advantage of the passive targeting (Luís et al. 2014). Since there are only two reported high 
affinity sites for ligands, it is supposed that a great amount of those TS262 and TS265 
molecules bind to the lower affinity sites of HSA. The isoelectric point of HSA is 4.7 at the 
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experimental pH (pH 7) (Vlasova & Saletsky 2009), which would reflect in a negative charge 
that could interact with the positive charge of the compounds. 
As the fluorescence quenching refers to excited-state reactions, molecular rearrangements, 
energy transfer, ground-state complex formation or collisional quenching (Varlan & Hillebrand 
2010), complementary studies are needed to understand the nature of the quenching induced 
by TS262 and TS265 on the BSA and HSA fluorescence. It would be also interesting to develop 
these fluorescence studies in order to obtain the binding affinity constants of the compounds to 
BSA and HSA. 
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IV. CONCLUSIONS AND FUTURE PERSPECTIVES 
The success of chemotherapy in cancer treatment is dependent on the development of such 
platforms capable of carry and delivers the chemotherapeutics in the desired cells, lessening 
the impact of toxic side effects on healthy cells. Bionanotechnology offers a wide range of 
innovations regarding drug delivery nanosystems to be used in medicine, which result in 
increased drug concentrations inside cancer cells, allowing higher doses compared with free 
drug. The present work describes the development of AuNPs-based systems – 
AuNPs@PEG@BSA and AuNPs@PEG@HSA - for carrying two metallic compounds with 
anti-proliferative potential, TS262 and TS265, in HCT116, A549 and H1975 cancer cell lines.  
In the current work it was verified the similarity in the TS262 and TS265 cytotoxicity within the 
same cancer cell line, in which the relative IC50 was determined in 0.714 ± 0.091 µM and 
0.741 ± 0.007 µM in A549 cell line, and 0.355 ± 0.038 µM and 0.349 ± 0.021 µM in H1975 cell 
line, for TS262 and TS265 respectively. The anti-proliferative effect of TS265 in MCF-10A has 
been reported as null at concentrations smaller than 1 µM. This is a positive result considering 
the relative IC50 for the TS265 compound in the three tested epithelia type cancer cell lines.  
A monodisperse solution of spherical AuNPs were successfully synthesised with a mean 
diameter of about 14 nm (14.26 ± 0.31 nm obtained by TEM and a mean hydrodynamic 
diameter of 14.14 ± 0.43 nm obtained by DLS) and a maximum and symmetric absorption peak 
observed at 519 nm. These particles were then functionalised, in which were obtained four 
different systems for drug delivery in cancer cells - AuNPs@PEG@BSA-TS262, 
AuNPs@PEG@BSA-TS265, AuNPs@PEG@HSA-TS262 and AuNPs@PEG@HSA-TS265 – 
with the maximum absorption peaks observed by UV-Vis at 533 nm, 535 nm, 529 nm and 
532 nm, and a mean hydrodynamic diameters obtained by DLS of 83.01 ± 1.43 nm, 
88.60 ± 5.80 nm, 76.21 ± 1.55 nm and 84.67 ± 1.68 nm, respectively. The cellular uptake of the 
functionalised AuNPs was confirmed by the cytotoxicity assays results in HCT116, A549 and 
H1975 cancer cell lines, and it was observed that the cellular response to AuNPs was 
dependent on the tested cancer cells type. Specifically, the nanosystems containing the TS265 
compound - AuNPs@PEG@BSA-TS265 and AuNPs@PEG@HSA-TS265 – showed the ability 
to reduce in vitro the required doses of the TS265 in HCT116, A549 and H1975 cancer cells. 
The AuNPs@PEG@HSA-TS262, tested under the same conditions, also showed to be a 
promising in vitro drug delivery system, able to reduce the required doses of TS262 in HCT116 
cancer cell line. The AuNPs@PEG@BSA-TS262 do not shown any advantage compared to 
TS262 administered alone in the HCT116 and H1975 cancer cell lines.  
ICP-MS allowed to calculate the amount of TS262 and TS265 molecules bound per 
AuNP@PEG@BSA (764 ± 120 and 612 ± 23 molecules, respectively) and per 
AuNP@PEG@HSA (307 ± 23 and 432 ± 8 molecules, respectively). The fluorescence assays 
were in agreement with these results, showing the interaction between the serum proteins, in its 
free form, and the compounds, at higher molar ratios compared to the ICP-MS results. 
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All pre-defined objectives for this thesis have been accomplished but there are still many 
milestones that can be further developed in the future: 
i) The anti-proliferative effect of free TS262 in MCF-10A healthy epithelial cells from 
mammary gland should be addressed; 
ii) It is important to pursue the studies trying to prove the potential of these 
nanosystems by decreasing the side toxic effects of chemotherapy, affecting less 
the healthy cells. In this regard, the AuNPs functionalised with the TS262 can bring 
advantages compared to the use of free drug in cancer treatment. For that, in vitro 
cytotoxicity assays in healthy cells (e.g. MCF-10A) should be performed, and if no 
toxicity from the functionalised AuNPs is verified, in vivo assays should be also 
carried out. The in vivo studies will allow knowing, beyond biocompatibility, if there 
is any AuNPs accumulation in organs which are not targeted, and also the blood 
circulation time of the particles. Non-targeted nanoparticles have been reported to 
significantly improve drug bioavailability and the high accumulation of anticancer 
agents in cancer cells due to EPR effect; 
iii) Understanding the mechanisms of AuNPs internalisation into cells is important for 
the drug delivery. Their internalisation is dependent on surface coating and AuNP 
size. Internalisation of AuNPs could be tracked, possible via transmission electron 
microscopy or fluorescent optical microscopy in order to study the mechanism of 
internalisation in living cells; 
iv) Adapting the developed nanosystems for active targeting and study the possible 
advantages compared to the passive targeting. Several molecular targeted agents 
have been studied for this purpose in order to obtain personalised therapies for 
each type of cancer. The epidermal growth factor receptor (EGFR) is a 
transmembrane tyrosine kinase receptor that is abnormally amplified and/or 
activated in a variety of cancers (Perez-Torres et al. 2006). More than 60 % of 
non-small cell lung carcinomas overexpress EGFR, making anti-EGFR therapies 
very attractive for the treatment of these cancer types (Santos et al. 2011). Tyrosine 
kinase inhibitors for EGFR, such as Erlotinib and Afatinib (American Cancer 
Society, 2014), and monoclonal antibodies against the extracellular domain of 
EGFR, e.g. Cetuximab have demonstrated an anti-proliferative effect on cancer 
cells (Doody et al. 2007, Hsu et al. 2010). A monoclonal antibody to vascular 
endothelial growth factor (VEGF), Bevacizumab, has been also used in targeted 
therapies for non-small cell lung cancers (American Cancer Society, 2014). The 
developed AuNPs can be functionalised in the future with any of these referenced 
agents for targeted therapies in lung cancers. In turn, the two most important 
targeted drugs in colorectal cancer include VEGF, a protein that regulates the 
process of angiogenesis, and EGFR pathways (Chee & Sinicrope, 2010). The 
anti-VEGF agents Bevacizumab and Ziv-aflibercept, and the anti-EGFR monoclonal 
antibodies Cetuximab and Panitumumab, are approved for the treatment of 
 
47 
 
colorectal cancer (American Cancer Society, 2013). As well as in non-small cell 
lung cancers, the EGFR are up-regulated in more than 60 % of colorectal cancer 
cases (Chee & Sinicrope, 2010), being an important target for the development of 
new therapies for colorectal cancer. Thus, either the referenced anti-VEGF or 
anti-EGFR agents can be used to functionalise the developed AuNPs for active 
targeting-based therapy in colorectal cancer; 
v) Complementary fluorescence studies are needed to understand the nature of the 
observed quenching of BSA and HSA due to the presence of the compounds, and it 
would be also interesting to develop these fluorescence studies in order to obtain 
the binding affinity constants of the TS262 to HSA and BSA, and the binding affinity 
constant of the TS265 to BSA. 
Although a wide range of nanomaterials have been used for cancer treatment, the 
bionanotechnology remains in early stages, and the safety of such materials in nanomedicine 
needs to be fully understood. However it is believed that the development of targeted and 
non-targeted nanosystems for drug delivery will bring a significant increase in the cure of 
several types of cancer in which treatments are not completely effective, or cancers do not have 
cures today. It is noteworthy that the four developed AuNPs-based nanosystems for drug 
delivery can be applied in nanomedicine, in principle, to a plethora of other cancer types. 
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VI. APPENDICES 
 
 
Figure VI.1 – Linear standard curve in the range of 0 – 0.5 mg/mL of PEG, measured at the wavelength of 
412 nm by UV-Vis spectroscopy. This standard curve supports the Ellman’s method and the quantification 
of thiolated chains per AuNP was determined after interpolation. The linear range is given by the following 
equation: Abs412 nm = 0.007x[PEG, µM] + 0.027. The data is relative to the mean of three independent 
assays and error bars are correspondent to SEM. 
 
Figure VI.2 – Linear standard curve in the range of 0 – 0.14 µM of BSA obtained by UV-Vis spectroscopy. 
This standard curve supports the Bradford assay and the quantification of BSA per AuNP was determined 
after interpolation. The linear range is given by the following equation: 
Abs(595/450)nm = 14.08x[BSA, µM] + 0.019. The data is relative to the mean of three independent assays 
and error bars are correspondent to SEM. 
 
Figure VI.3 – Linear standard curve in the range of 0 – 0.14 µM of HSA obtained by UV-Vis spectroscopy. 
This standard curve supports the Bradford assay and the quantification of HSA per AuNP was determined 
after interpolation. The linear range is given by the following equation: 
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Abs(595/450)nm = 8.014x[HSA, µM] + 0.043. The data is relative to the mean of three independent assays 
and error bars are correspondent to SEM. 
 
Figure VI.4 – Spectra corresponding to the maximum absorbance wavelengths of TS262 and TS265 
compounds – 254 and 253 nm, respectively – obtained by UV-Vis spectroscopy in the range frequency of 
200 - 280 nm, in a milli-Q H2O solution. 
 
Figure VI.5 – Spectra corresponding to the AuNPs@PEG@BSA, AuNPs@PEG@BSA-TS262, 
AuNPs@PEG@BSA-TS265, obtained by UV-Vis spectroscopy in the range frequency of 200 - 800 nm, in 
a pH 7.0 solution. The maximum absorbance peak at 254 nm and 253 nm can confirmed the presence of 
TS262 and TS265, respectively, on AuNPs surface. 
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Figure VI.6 – Spectra corresponding to the AuNPs@PEG@HSA, AuNPs@PEG@HSA-TS262, 
AuNPs@PEG@HSA-TS265, obtained by UV-Vis spectroscopy in the range frequency of 200 - 800 nm, in 
a pH 7.0 solution. The maximum absorbance peak at 254 nm and 253 nm can confirmed the presence of 
TS262 and TS265, respectively, on AuNPs surface. 
 
Figure VI.7 – Standard curve in the range of 2.5 – 30 µM of TS262, measured at the wavelength of 254 nm 
by UV-Vis spectroscopy. It allows the determination of the TS262 molar extinction coefficient through 
Lamber-Beer law, and was determined in 55300 M
-1
 cm
-1
. 
 
 
Figure VI.8 – Standard curve in the range of 2.5 – 30 µM of TS265, measured at the wavelength of 253 nm 
by UV-Vis spectroscopy. It allows the determination of the TS265 molar extinction coefficient through 
Lamber-Beer law, and was determined in 34900 M
-1
 cm
-1
. 
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